Infectious diseases in Finland 2013 by Jaakola, Sari et al.
Infectious Diseases 
in Finland 2013
Sari Jaakola
Outi Lyytikäinen
Ruska Rimhanen-Finne
Saara Salmenlinna
Carita Savolainen-Kopra
Jaana Pirhonen
Jaana Vuopio
Jari Jalava
Maija Toropainen
Hanna Nohynek
Salla Toikkanen
Jan-Erik Löflund
Markku Kuusi
Mika Salminen
(ed.)
Re
po
Rt
Re
po
Rt
Sari Jaakola, Outi Lyytikäinen, Ruska Rimhanen-Finne, Saara Salmenlinna,  
Carita Savolainen-Kopra, Jaana Pirhonen, Jaana Vuopio, Jari Jalava, Maija Toropainen, 
Hanna Nohynek, Salla Toikkanen, Jan-Erik Löflund, Markku Kuusi, Mika Salminen (ed.) 
 
Infectious Diseases in Finland 2013
publication sales
www.thl.fi/bookshop
telephone: +358 29 524 7190
Fax: +358 29 524 7450 18 | 201418 | 2014
ISBN 978-952-302-193-8
The report Infectious Disease in Finland provides an overview of the key pheno-
mena, epidemics and prevalence of infectious diseases during the year. The topics 
covered by the report include respiratory infections, intestinal infections, hepati-
tis, sexually transmitted diseases and antimicrobial resistance.
In 2013 Salmonella Typhimurium infections were caused by unpasteurised milk. 
EHEC caused two fairly large clusters. The hepatitis A outbreak in the Nordic count-
ries was linked to frozen berries. Nearly 200 people fell ill in a hotel in Espoo, and 
the cause of the outbreak was confirmed in laboratory tests as norovirus. There 
are still considerable regional differences in the incidence of Clostridium difficile. 
An epidemic caused by K. pneumoniae carbapenemase (KPC)-producing bacteria 
was for the first time confirmed in Finland. Streptococcus pneumoniae serotypes 
caused invasive disease in five unvaccinated children aged under 2 years.
The report Infectious Diseases in Finland compares the most recent data to data 
from previous years in order to describe more long-term trends in infectious di-
seases. The report data are collated from the Infectious Diseases Register of the 
National Institute for Health and Welfare (THL).
9 789523 021938
In
fectiou
s D
iseases in
 Fin
lan
d 2013
InfectIous DIseases In fInlanD 2013
Report 18/2014
Jaakola sari, lyytikäinen outi, Rimhanen-finne Ruska, salmenlinna saara,  
savolainen-Kopra carita, Pirhonen Jaana, Vuopio Jaana, Jalava Jari, toropainen Maija,  
Nohynek Hanna, Toikkanen Salla, Löflund Jan-Erik, Kuusi Markku, Salminen Mika (ed.)
© Publisher
National Institute for Health and Welfare (THL)
Department of Infectious Disease Surveillance and Control
P.O. Box 30 (Mannerheimintie 166)
FI-00271 Helsinki
Tel. +358 29 524 6000
http://www.thl.fi/infektiotaudit
Editors: Sari Jaakola, Outi Lyytikäinen, Ruska Rimhanen-Finne, Saara Salmenlinna, Carita Savolainen-Kopra, 
Jaana Pirhonen, Jaana Vuopio, Jari Jalava, Maija Toropainen, Hanna Nohynek, Salla Toikkanen, Jan-Erik Lö-
flund, Markku Kuusi and Mika Salminen.
In addition to commentary, the report includes figures and tables that are not employed in our regular report-
ing. Distributions by gender, age and region are available on our website. The figures for some of the diseases 
in the National Infectious Diseases Register (NIDR) will still be updated after the figures have been published 
in print.
Up-to-date figures are available at http://tartuntatautirekisteri.fi/tilastot
Layout: Kati Tiirikainen
Infectious Diseases in Finland 2013.
National Institute for Health and Welfare, Report 18/2014
ISBN (printed) 978-952-302-193-8
ISSN (printed) 1798-0070
ISBN (online) 978-952-302-194-5
ISSN (online) 1798-0089
http://urn.fi/URN:ISBN:978-952-302-194-5
Juvenes Print – Suomen yliopistopaino Oy
Tampere
Report 18/2014
National Institute for Health and Welfare
Infectious Diseases in Finland 2013
3
contents
IntroductIon • 5
respIratory InfectIons • 7
Adenovirus ................................................................................................................................................ 7
Influenza ................................................................................................................................................... 7
Parainfluenza ............................................................................................................................................ 9
Rhinovirus ................................................................................................................................................ 9
RSV ........................................................................................................................................................ 10
Whooping cough .................................................................................................................................... 10
Chlamydia pneumoniae .......................................................................................................................... 11
Legionella ............................................................................................................................................... 11
Mycoplasma pneumoniae ....................................................................................................................... 12
GastroIntestInal InfectIons • 13
Food-borne epidemics ............................................................................................................................. 13
Clostridium difficile .................................................................................................................................. 15
Enterohaemorrhagic Escherichia coli (EHEC) .......................................................................................... 16
Campylobacter........................................................................................................................................ 16
Listeria .................................................................................................................................................... 16
Salmonella .............................................................................................................................................. 18
Shigella ................................................................................................................................................... 19
Yersinia ................................................................................................................................................... 19
Norovirus ................................................................................................................................................ 20
Rotavirus ................................................................................................................................................ 21
HepatItIs • 22
Hepatitis A ............................................................................................................................................. 22
Hepatitis B.............................................................................................................................................. 22
Hepatitis C ............................................................................................................................................. 22
sexually transmItted dIseases • 25
Chlamydia .............................................................................................................................................. 25
Gonorrhoea ............................................................................................................................................ 25
Syphilis ................................................................................................................................................... 26
HIV and AIDS ....................................................................................................................................... 26
antImIcrobIal resIstance • 28
MRSA .................................................................................................................................................... 28
VRE........................................................................................................................................................ 28
ESBL ...................................................................................................................................................... 29
tuberculosIs • 32
Tuberculosis ............................................................................................................................................ 32
otHer InfectIons • 36
Invasive pneumococcal disease ................................................................................................................ 36
Haemophilus .......................................................................................................................................... 37
Meningococcus ....................................................................................................................................... 38
MMR diseases (measles, mumps, rubella) ............................................................................................... 39
4
Report 18/2014
National Institute for Health and Welfare
Infectious Diseases in Finland 2013
Varicella virus .......................................................................................................................................... 39
Borrelia (Lyme disease) ........................................................................................................................... 40
Tick-borne encephalitis (TBE) ................................................................................................................ 40
Puumala virus ......................................................................................................................................... 42
Pogosta disease ........................................................................................................................................ 42
Tularemia ................................................................................................................................................ 43
Rabies ..................................................................................................................................................... 43
Malaria, dengue fever and other travel-related infections ......................................................................... 43
Blood and cerebrospinal fluid findings in children .................................................................................. 45
Blood and cerebrospinal fluid findings in adults ...................................................................................... 52
autHors • 66
Report 18/2014
National Institute for Health and Welfare
Infectious Diseases in Finland 2013
5
Introduction
The entry into force, on 6 November 2013, of Deci-
sion no 1082/2013/EU of the European Parliament 
and of the Council on serious cross-border threats to 
health entailed a significant change in cooperation at 
EU-level on the surveillance and prevention of infec-
tious diseases. The Decision automatically attained 
legal validity in Member States and increased the 
Commission’s powers to act not only in the preven-
tion and surveillance of infectious diseases, but also 
with regard to environmental and chemical threats. 
The decision defines/specifies i.a.  the EU system for 
the surveillance of infectious diseases, as well as the 
related national competent authorities (National In-
stitute for Health and Welfare (THL) in Finland); 
the Early Warning and Response System (‘EWRS’) 
and its national representatives (the Ministry of So-
cial Affairs and Health, and the National Institute for 
Health and Welfare (THL)) and the Health Security 
Committee, responsible for coordinating the preven-
tion of cross-border threats to health, composed of 
representatives of Member States’ competent authori-
ties (Ministry of Social Affairs and Health).
The Decision clearly expands the powers of the Com-
mission in terms of cross-border threats and obliges 
Member States to exchange information and coor-
dinate preventive measures more efficiently than be-
fore.
It also provided the Commission with the authority 
to require reports from Member States on their pre-
paredness and contingency plans and facilitates the 
conclusion of joint procurement contracts for EU-
wide medical countermeasures, e.g. vaccines and 
medicines.
No significant changes occurred in national coopera-
tion in the surveillance and prevention of infectious 
diseases in 2013 – unless the budget cuts, based on 
a Government decision, targeted at research activities 
in the administrative sector of the Ministry of Social 
Affairs and Health are regarded as such. These cuts 
will affect the National Institute for Health and Wel-
fare as a whole and result in annual cutbacks in activi-
ties until at least 2017. As a result, the Department of 
Infectious Disease Surveillance and Control was also 
forced to implement staff reductions totalling five per-
son-years, and to considerably reduce some of its mi-
crobe typing activities (Yersinia and Clostridium diffi-
cile). When developing the system for the surveillance 
of infectious diseases, preparations must be made for 
cuts known to be forthcoming in years to come.
In 2013, the national social welfare and health care 
reform remained incomplete, resulting in a signifi-
cant delay in the overhaul of the Communicable 
Diseases Act. When this report was written, the prin-
ciples underlying the social welfare and health care 
reform were clear and had been agreed. It is therefore 
possible that preparation of the Act will be completed 
by 2014 and will enter into force in 2015. This may 
involve changes, particularly in the division of duties 
and coordination of the regional and local prevention 
of infectious diseases, but may also facilitate closer 
cooperation between regional and national activities. 
The objectives of the drafting of the Act include en-
hancing the surveillance of healthcare-associated in-
fections and improving the preconditions for their 
prevention.
EpidEmiological ovErviEw 
2013
The influenza epidemic season in 2012−2013 turned 
out to be longer than in the previous season, with over-
lapping epidemics of both influenza A and B in Janu-
ary to February. Influenza A(H1N1)pdm09 emerged 
as the season’s dominant virus, but the A(H3N2) 
viruses dominant in the previous season were also 
present throughout the country. Conforming with 
its typical pattern of seasonal variation, the RSV epi-
demic was smaller in scale than in the previous year. 
Virological surveillance of respiratory virus infections 
at sentinel sites included rhinovirus infections, which 
were diagnosed at a steady rate in both the autumn 
and spring season, whereas the mycoplasma epidemic 
that peaked in 2012 seems to have fallen back to its 
between-epidemic levels. The number of whooping 
cough cases was lower year-on-year. Fewer cases of 
tuberculosis were reported than in earlier years, but 
those who contracted the disease were younger than 
before. The fact that one third of cases were identi-
fied in foreign-born individuals is indicative of the 
gradual demographic change in epidemiology, as 
the number of cases of reactivation in the aged falls 
steadily. Pulmonary tuberculosis treatment outcomes 
rivalled those of most Member States, although they 
do not yet meet the WHO’s targets in full.
Several severe food-borne epidemics were detected 
during the year, including a Salmonella Typhimu-
rium epidemic resulting from sales of non-pasteur-
ised milk, and two fairly extensive clusters caused 
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by EHEC. Background analyses strongly indicated 
food-borne infection, but the actual source of infec-
tion remained unidentified. An inter-Nordic hepati-
tis A epidemic was identified and was the probable 
cause of at least 11 cases in Finland. A strain with 
an identical genome was detected in the other Nor-
dic countries, except Iceland. Frozen berries were the 
most probable source of infection. The number of 
hepatitis A cases was therefore five times higher than 
in the previous year.
The cause of an epidemic which affected almost 200 
people in an Espoo hotel was initially difficult to 
identify and was not revealed until an expert labo-
ratory identified it as a norovirus. The numbers of 
campylobacter and Clostridium difficile cases were 
somewhat lower than in the previous year. However, 
campylobacter remains the most common bacterial 
cause of gastroenteritis in Finland, but the reasons for 
its seasonal variation are not fully understood. No-
table regional differences remain in the incidence of 
Clostridium difficile.
The fairly stable epidemiologal status of sexually trans-
mitted diseases and HIV infection continued but, as 
in other Nordic countries, chlamydia infections con-
tinue to be notably common in Finland. With regard 
to gonorrhoea, so-called sex tourism seems to be a 
significant background factor in infections contract-
ed abroad. Of hepatitis viruses, a higher number of 
cases of type C are still being reported at annual level. 
In the near future, the possibility of medical eradica-
tion will provide new options for the prevention of 
infections. However, in order to influence incidence 
in any major way, treatment should cover a signifi-
cant part of the high-risk group. This would require 
the creation of efficient treatment models adapted for 
intravenous drug users.
Although a major percentage of the bacterial strains 
producing carbapenemase were of foreign origin, the 
first actual local epidemic caused by K. pneumoniae 
that had the KPC carbapenemase gene, was analysed 
in Finland. The number of MRSA cases and MRSA 
blood culture findings remained on a par with previ-
ous years, while the number of VRE cases decreased 
and the number of ESBL E. coli findings continued to 
grow. Only six cases of severe pneumococcal diseases 
caused by vaccine serotypes were detected in under 
2-year-olds and all but one in unvaccinated children. 
The percentage of penicillin-resistant pneumococcal 
strains and those with reduced susceptibility began 
to fall.
The situation remained excellent with regard to mea-
sles, mumps and rubella (MMR diseases), thanks to 
high vaccination coverage. Only a handful of cases 
were detected, almost all of them being connected 
with unvaccinated persons travelling abroad.
The number of meningococcus infections decreased 
by one third in comparison with the three previous 
years. In Finland, conscripts in military service receive 
a quadrivalent polysaccharide vaccine, but otherwise 
meningococcus vaccines are mainly used in connec-
tion with travel and epidemics. The majority of cases 
caused by serogroup B involved young children; with 
regard to group Y, older age groups are the dominant 
category.
The number of tick-borne disease cases, both tick-
borne encephalitis (TBE) and borrelia, remained on 
a par with previous years.
Via tourism, infectious diseases were carried to Fin-
land – including diseases that only occur abroad, such 
as malaria and dengue fever, as well as a considerable 
number that have been eradicated or become rare 
in this country either through vaccinations or other 
preventive measures, such as salmonella, legionella, 
various sexually transmitted diseases and hepatitis A 
viral infections. Fifty people were exposed to rabies 
abroad.
Helsinki, 16 May 2014
Mika Salminen
Head of Department
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Respiratory infections
The 2012–2013 epidemic season for influenza A proved longer than the previous • 
season.
The influenza B epidemic occurred concurrently with the influenza A epidemic, in • 
December–May.
As expected, the RSV epidemic was smaller than the winter epidemic a year • 
before.
The number of • Mycoplasma pneumoniae cases fell back to the level common 
between epidemics.
The number of whooping cough cases was distinctly lower than in 2012.• 
adEnovirus
In 2013, 700 confirmed cases of adenovirus infection 
were recorded (2012: 677). The largest number of 
cases occurred in the under 5 age group, but numer-
ous cases also came to light in the 5 to 9, 15 to 19 and 
20 to 24 age groups. The incidence was highest in No-
vember (more than 80 cases per month) and lowest in 
July and August (approximately 40 per month).
There are 57 known types of adenovirus. Some of 
them cause respiratory infections, while others cause 
gastrointestinal, eye or other infections. Adenoviruses 
are common pathogens in infants and small children; 
they occur more rarely in adults. No actual adenovi-
rus epidemic was recorded in 2013, but adenoviruses 
occurred steadily throughout the year.
Laboratories use various testing methods to detect 
adenoviruses in clinical samples. Antigen detection, 
virus cultures and PCR are sensitive and reliable 
methods used at specialised virus laboratories.
influEnza
In winter 2013, the epidemic season began in Jan-
uary, peaked in February and continued until mid-
April. Viruses of the influenza A(H1N1)pdm09 sub-
type emerged as the epidemic dominant virus in the 
2012−2013 season. Influenza A(H3N2) and B virus-
es occurred simultaneously with the dominant virus.
Influenza  a
In 2013, 6,061 findings of influenza A were reported 
to the National Infectious Diseases Register NIDR, 
almost the same number as in the previous year 
(2012: 5960). National surveillance of influenza vi-
rus infections at the virology unit of the National In-
stitute for Health and Welfare led to the detection of 
220 influenza A infections, more than 80% of which 
had been caused by the influenza A(H1N1)pdm09 
virus.  During the epidemic season, both influenza A 
viruses (H1N1pdm09 and H3N2) were in circula-
tion concurrently. The first isolated cases of influenza 
A infections were reported in autumn 2012, and an 
increasing number in December. Data in the NIDR 
and from the national influenza surveillance of the 
National Institute for Health and Welfare indicate 
that the epidemic in the 2012−2013 season peaked 
in weeks 5 to 11. During April, the number of cases 
began to decline gradually, until only isolated influ-
enza A infections were being reported in May. The 
2012−2013 epidemic season lasted longer than the 
previous one. Influenza A infections were found in 
all age groups. Although the national influenza vac-
cination programme offers a seasonal influenza vac-
cination free of charge for children in risk groups 
and their inner circle, and healthy children aged 6 to 
35 months, the highest number of influenza A cases 
(n=708) was reported in the 0 to 4 year age group. 
Reasons for the elevated morbidity in this age group 
may include poor vaccination coverage, which may 
have been influenced by the news coverage of the as-
sociation between the 2009 pandemic vaccination 
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Figure 1. Cases of influenza A by month, and epidemic virus serotypes 2002–2013 (no. of cases).
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(Pandemrix) and cases of narcolepsy, and false no-
tions of the prevalence and severity of the influenza 
outbreak.
The genetic diversity of both the influenza A(H1N1)
pdm09 and A(H3N2) viruses has increased in recent 
years. Several genetic groups were found in both in-
fluenza A subtypes in 2013.
Four years since they appeared, the diversity of 
A(H1N1)pdm09 viruses has increased and several ge-
netic groups circulating as epidemics have been iden-
tified. The cases of influenza A(H1N1)pdm09 iden-
tified during the 2012−2013 epidemic season repre-
sented two genetic groups which are also frequently 
found elsewhere in Europe; no antigenic differences 
were detected between these groups or between them 
and the A/California/07/2009 vaccine virus.
The epidemic viruses of the influenza A(H3N2) group 
circulating worldwide comprised two distinct genet-
ic groups, Perth/16/2009 and Victoria/208/2011, 
with some antigenic differences. Further genetic sub-
groups may be detected within these two groups. 
In 2012, the occurrence of viruses belonging to the 
Victoria/208/2011 lineage increased and a virus of 
the Victoria/208/2011 lineage was introduced in 
the season’s influenza vaccine A(H3N2) for the sea-
son 2012−2013. Influenza A(H3N2) viruses found 
in Finland during the 2012−2013 epidemic season 
were all of the Victoria/207/2011 lineage, belonging 
to a genetic subgroup whose viruses circulated abun-
dantly in other parts of Europe.
Influenza b
Following the weak influenza B epidemic of 2012, a 
total of 1,692 cases of influenza B were reported to the 
NIDR in 2013 (2012: 464). The influenza B epidem-
ic of the winter of 2013 coincided (December−May) 
with the influenza A epidemic. Influenza B virus in-
fections were diagnosed in all age groups.
Of the two influenza B virus lineages that have cir-
cled the world in recent years, the occurrence of the 
Yamagata lineage increased in 2012. In the epidemic 
season 2012−2013, viruses of both the Victoria and 
Yamagata lineage were found in Finland. However, the 
majority of Finnish influenza B viruses were of the Vic-
toria lineage, which differed from the virus contained 
in the vaccine. Small numbers were reported of the 
two Yamagata lineage viruses that are circulating the 
world, which differ from one another genetically and 
are slightly divergent in terms of their antigenes.
Vaccine for the epidemic season 2013−2014
Based on reports of the influenza A and B epidemic 
viruses circling the world, the WHO recommended a 
change to the vaccination composition in the North-
ern Hemisphere for the epidemic season 2013−2014. 
The recommendation was that the influenza A(H3N2) 
virus component be changed to A/Texas/50/2012, 
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Figure 2. Cases of influenza B by month, and epidemic virus serotypes 2002–2013 (no. of cases).
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which has a better antigenic correspondence to the 
viruses similar to A/Victoria/361/2011 that are circu-
lating as epidemics. The influenza A(H1N1)pdm09 
component remained unchanged, in the form of the 
A/California/07/2009 virus.
The influenza B virus component was changed to B/
Massachusetts/2/2012, that continued to represent 
viruses of the Yamagata lineage, but differed antigeni-
cally from the influenza B virus component previous-
ly used in the vaccine.
season 2013−2014
The first cases of influenza A and B infections were re-
ported in November and December 2013. The season 
2013−2014 began slowly, with the number of influ-
enza cases increasing gradually in December–January 
and peaking around mid-February. Both influenza 
A viruses were reported during the season, although 
the influenza A(H1N1)pdm09 virus emerged as the 
dominant strain. Individual cases of infections caused 
by an influenza B virus of the Yamagata lineage were 
reported.
A more detailed analysis of the epidemic viruses cir-
culating Finland in the 2012−2013 season has not yet 
been completed, but preliminary findings show that 
the epidemic influenza A viruses found were very simi-
lar to the influenza A(H3N2) and influenza A(H1N1)
pdm09 and influenza B components contained in the 
seasonal vaccine. In February 2014, the WHO issued 
a new vaccine recommendation for the northern hemi-
sphere 2014−2015 epidemic season, based on the then 
current epidemic situation, recommending that no 
changes be made to the composition of the vaccine.
Campaigning for the seasonal influenza vaccination 
continued to emphasise the fact that in the 2013−2014 
season the close contacts of any person prone to severe 
influenza should be vaccinated as part of the national 
vaccination programme. The data on the coverage of 
the seasonal influenza vaccination in the 2013−2014 
season will be completed by the end of April.
parainfluEnza
Parainfluenza viruses are grouped under one heading 
in the NIDR, even though laboratories usually differ-
entiate between parainfluenza viruses 1, 2 and 3. In 
2013, 429 parainfluenza infections were confirmed 
(2012: 401), most of them in the 0 to 4 age group. 
The highest monthly number of cases (80–108) was 
recorded in April–May and December (71). Parain-
fluenza infections are found in all age groups. A 
child’s first parainfluenza infections may lead to a 
severe condition, even requiring hospitalisation. In 
an older child or an adult, a parainfluenza infection 
is typically much milder in its symptoms. It often 
presents as an ordinary upper respiratory tract infec-
tion and requires no laboratory diagnostics. In special 
groups, however, such as immune deficiency patients, 
parainfluenza viruses can cause quite serious symp-
toms. Parainfluenza virus type 3 causes minor epi-
demics in the summer and autumn nearly every year. 
Type 1 and 2 viruses, on the other hand, do not cause 
epidemics every year. Parainfluenza viruses, especially 
type 1, typically cause laryngitis in small children.
10
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Figure 3. Cases of RSV per month, 2002–2013 (no. of cases).
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rhinovirus
In 2013, more than 420 confirmed cases of rhino-
virus infection were recorded (2012: 211). The inci-
dence was highest in May, October and November 
(ca. 50/month) and lowest in January (12/month). 
Almost 60% of these infections were diagnosed in 
children under the age of 4.
More than 150 types of rhinovirus are known. They 
are the most common cause of mild respiratory in-
fections. Rhinoviruses are most common in young 
children, but are present in all age groups. In 2013, 
rhinovirus infections were reported in several garri-
sons. In spring 2013, the rhinovirus epidemic partly 
coincided with the peak of the parainfluenza season 
in May. Typically, the rhinovirus epidemic of the au-
tumn began after the start of the school term in Au-
gust and continued fairly steadily throughout the au-
tumn season.
Since August, rhinoviruses have been included in the 
surveillance of respiratory virus infections conduct-
ed at the virology unit of the National Institute for 
Health and Welfare (THL), which may partly con-
tribute to the increase in the number of cases. Lab-
oratories use the PCR test to detect rhinoviruses in 
clinical samples. This test is extremely sensitive and 
reliable. Specialised virus laboratories are also able to 
culture rhinoviruses.
rsv
In 2013, 1,997 cases of RSV confirmed by labora-
tory tests were reported to the NIDR (2012: 2345). 
Through long-term surveillance, a major RSV epi-
demic has been observed in Finland every other win-
ter, often starting in November–December, with a 
minor epidemic occurring between the major ones. 
As expected, the major winter epidemic of 2012 was 
followed by a minor epidemic that began in Janu-
ary 2013 and continued until May. The incidence of 
RSV varied by hospital district (4−79/100,000), most 
probably due to differences in the use of laboratory di-
agnostics. As in earlier years, the majority of RSV cas-
es (almost 90%) were found in children aged 0 to 4. 
Although RSV infections are present in all age groups, 
cases requiring hospitalisation and laboratory diag-
nostics mainly involved infants and small children.
Reliable quick tests for RSV diagnostics have been 
developed for use at health centres, outpatient clin-
ics and hospitals. In hospital conditions, RSV is eas-
ily transmitted between patients. Quick tests make 
it easier to identify RSV infections and therefore to 
prevent further transmission. Specialised virus labo-
ratories increasingly use genetic replication methods 
for diagnosing RSV.
whooping cough
In 2013, the number of whooping cough cases re-
ported to the NIDR totalled 192 (3.6/100,000). This 
was clearly less than in 2012 (536; 9.9/100,000). The 
cases were concentrated in the 0 to 14 age group, four 
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Figure 4. Cases of whooping cough in children’s and young adults’ age groups 2002–2013 (no. of cases).
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of the patients being under the age of 12 months and 
three of them under the age of three months. The di-
agnosis of all patients under 12 months old was based 
on a PCR test, while the majority of cases were diag-
nosed from antibody testing (178).
In 2013, all of the strains found, except for one strain 
of B. pertussis (1/5), produced pertactin, one of the 
components of the vaccine used in Finland.
As in earlier years, the incidence of whoop-
ing cough varied considerably by hospital district 
(0−13.7/100,000), being highest in the Kanta-Häme 
Hospital District. No cases were reported in the 
Åland Islands, Itä-Savo, Lapland and Länsi-Pohja 
hospital districts.
Choosing an optimum vaccination strategy for 
whooping cough is difficult, as the available vaccines 
are incomplete in efficiency and duration. A booster 
for six-year-olds was added to the national vaccina-
tion programme in Finland in 2003. In 2005, the 
whole-cell vaccine was replaced with a cell-free com-
bination vaccine containing the pertussis antigen for 
children in the age groups covered by child care clin-
ics. Until 2007, adolescent vaccinations were given 
between the ages of 11 and 13. Since 2009, the rec-
ommendation has been to vaccinate adolescents at 
the age of 14 to 15, i.e. beginning in the 8th grade 
of comprehensive school. Due to this transition, very 
few of these vaccinations were administered between 
2009 and 2011. This created a temporarily less well 
protected cohort in adolescent age groups. Illness in 
infancy indicates insufficient herd immunity. Never-
theless, Finland has so far been spared the extensive 
whooping cough epidemic that generated more than 
40,000 cases in the USA and almost 10,000 cases in 
the UK during 2012. In 2012, the year the epidemic 
occurred, on the basis of an extensive strain collection 
in the United States it was discovered that 60% of 
B.pertussis strains did not produce pertactin.
chlamydia pnEumoniaE
In 2013, 285 cases of Chlamydia pneumoniae were 
reported based on antibody testing. Relative to the 
population, the highest incidence was recorded in the 
hospital districts of Vaasa and Lapland (12/100,000). 
In the South Karelia, Kainuu, Kymenlaakso, Länsi-
Pohja and Satakunta hospital districts, the incidence 
(9/100,000) was also above the national average 
(5/100,000). The number of reported infections was 
highest among 10 to 24-year-olds, but cases can be 
found in all age groups.
lEgionElla
In 2013, 32 cases of legionellosis were reported. Four 
of these were diagnosed on the basis of two labora-
tory tests; 11 findings were based on the detection 
of the antigen in the urine, four on the isolation of 
the bacterial strain, one on the detection of nucleic 
acid in sputum, and 20 on serological methods. Fur-
ther investigation revealed that the clinical presenta-
tion was consistent with legionella pneumonia in 15 
cases (47%). Of a total 15 such cases, 11 tested posi-
tive for the presence of the legionella antigen in the 
urine, the bacterial strain was isolated in three cases 
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Figure 5. Cases of Mycoplasma pneumoniae and Chlamydia pneumoniae per month, 2002–2013 (no. of cases).
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and serological proof was found in four cases. All ex-
cept five of the patients had been abroad before fall-
ing ill, nine in European countries and one in the Far 
East. One infection of domestic origin was fatal. 80% 
of the patients with legionella pneumonia were male, 
with an average age of 56 (52−67) years. Of all cases 
found positive in the culture, three were pneumonias 
belonging to L. pneumophila serogroup 1 and one L. 
longbeachae wound on the palm was related to the 
handling of flowerbed soil.
Various premises (home, residential home, health 
centre) were investigated in more detail as possible 
sources of infection in the case of one patient who 
contracted the illness in Finland. Before cleaning 
measures were taken, legionella concentrations in 
the examined water systems were 500−30,000 cfu/l 
(colony forming units per litre) and, afterwards, only 
100 cfu/l at most. The threshold for measures requir-
ing cleaning is >1,000 cfu/l according to the Euro-
pean guideline for legionella, which is followed in 
Finland.
Internationally, the EIA antigene test of urine is the 
most commonly used method of diagnosis. Reports 
on EIA based methods indicate that microtitre plate 
based tests would be both more sensitive and specific 
than membrane based tests.
Accommodation data related to all of the patients who 
fell ill abroad was reported to ELDSNET (European 
Legionnaires’ Diseases Surveillance Network), which 
collects data on travel-related cases of legionellosis. 
European surveillance indicates that the majority (ca. 
60−70%) of cases are of community origin, some 
20% are associated with travel and fewer than 10% 
originate in hospitals. In Finland, cases of legionello-
sis are most often linked with travel. Legionellosis is 
not often  suspected in cases of pneumonia of domes-
tic origin, contracted outside hospitals.
mycoplasma pnEumoniaE
In winter 2011−2012, Finland experienced the sec-
ond peak of a dual-peak Mycoplasma pneumoniae epi-
demic. In 2013, the total number of M. pneumoniae 
cases was 3,026, having exceeded 4,600 in 2012 and 
more than 7,800 in 2011. Hence, we are once again 
in the lull between epidemics.
As in the previous year, the majority of cases (more 
than 1,000) were recorded in the Helsinki and Uusi-
maa Hospital District. More than 60% of these cases 
were detected in individuals aged 5−24. The inci-
dence was highest in the Hospital District of Itä-Savo 
(190/100,000).
As the lull between epidemics is likely to last 4 to 7 
years, now is the time to improve the related diag-
nostics. No study has been performed before now of 
the macrolide resistance of M. pneumoniae, which has 
increased in other parts of the world in recent years. 
However, preliminary findings indicate that resistant 
strains based on mutations described elsewhere are 
also present in this country.
Report 18/2014
National Institute for Health and Welfare
Infectious Diseases in Finland 2013
13
Gastrointestinal infections
Frozen strawberries were suspected as the source of a Nordic epidemic of • 
hepatitis A. In order to prevent infections, a recommendation was issued that 
frozen berries of foreign origin be heated before use.
Almost 200 people contracted gastroenteritis in May–June after visiting a hotel • 
in Espoo. Exceptionally, ordinary diagnostic methods were unable to detect a 
norovirus in patient samples.
The number of • Clostridium difficile cases has continued to decline. Notable 
regional differences in incidence rates continue.
EHEC was the cause of two fairly extensive clusters. In one of these, the suspected • 
probable source of infection was widely circulated food and, in the other, the 
connecting factor was day care food.
Slightly fewer findings of campylobacter were reported to the National Infectious • 
Diseases Register than in the previous year, but campylobacter still remains the 
most common bacterial cause of gastrointestinal infections in Finland.
The number of listeria cases reported was equal to that of the previous year. More • 
than one half of patients were aged over 75 in this case.
food-bornE EpidEmics
Since the beginning of 2010, municipal epidemic 
investigation working groups have entered notifica-
tions of suspected food- and water-borne epidemics 
directly into the register IT system jointly maintained 
by the National Institute for Health and Welfare and 
the Finnish Food Safety Authority Evira. This system 
is known as the RYMY information system. In 2013, 
the National Institute for Health and Welfare con-
ducted a user survey, which indicated that the sys-
tem’s strengths included ease of entering notifications 
of suspected cases, rapid communication of informa-
tion between various actors, and the users’ commit-
ment to and positive attitude towards the electronic 
reporting system. Listed system weaknesses included 
poor usability, a lack of reporting features and the 
slow implementation of proposed modifications and 
suggested improvements to the system. The future 
challenge is to construct a system that would contrib-
ute to higher efficiency in analysing and preventing 
epidemics, and enhancement of the quality of inves-
tigations.
The National Institute for Health and Welfare sup-
ports municipal epidemic investigation working 
groups focusing on food- and water-borne epidemics 
and, whenever necessary, coordinates the investiga-
tion of epidemics e.g. if the epidemic in question is 
exceptionally severe or geographically widespread. In 
2013, 73 notifications of suspected cases were entered 
in the RYMY information system (in 2012: 88) and 
the National Institute for Health and Welfare con-
tacted the municipal epidemic investigation working 
group with regard to 26 notifications. Several other 
gastrointestinal infection clusters were investigated as 
well.
The National Institute for Health and Welfare is also 
involved in the Epidemic Intelligence Information 
System EPIS, coordinated by the European Centre 
for Disease Prevention and Control (ECDC), which, 
in case epidemics arise, enables European countries 
to provide and gain information on epidemic inves-
tigations in other countries. In 2013, the National 
Institute for Health and Welfare participated in the 
prevention of 37 international bacterial gastrointes-
tinal epidemics by providing up-to-date information 
on the situation in Finland via EPIS. Four EPIS que-
ries were sent from Finland regarding two domestic 
epidemics of EHEC O157, one of which was S. Ty-
phimurium FT 120, the other being S. Typhimurium 
FT U311. Moreover, in the Molecular Surveillance 
Pilot project, coordinated by ECDC, the National 
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Institute for Health and Welfare participated in the 
investigation of seven (S. Enteritidis FT 8, S. Vir-
chow, S. Kentacky and four Listeria monocytogenes) 
international epidemic clusters.
eHec caused two fairly extensive clusters
In April-May, ten people were infected with a sorbi-
tol-fermenting EHEC O157:H7 (FT 88, stx2, hlyA, 
eae) strain. The same EHEC strain was found in three 
patients in December, in addition to which a family 
member of one patient was diagnosed with haemolyt-
ic-uremic syndrome (HUS) without an EHEC find-
ing in the faeces. The patients were children aged 1 
to 8. Interviews did not reveal any particular event or 
farm visit, consumption of non-pasteurised milk or a 
meal in a certain restaurant or restaurant chain that 
would have constituted a connecting factor between 
the patients. Because the patients came from differ-
ent parts of Finland, it is probable that the source of 
infection was widely circulated food or another prod-
uct contaminated by the EHEC bacteria. According 
to the expert network of the European Centre for 
Disease Prevention and Control, no similar bacterial 
strain had been found in other European countries or 
the United States.
In Lohja, an epidemic caused by the EHEC O157:H7 
(FT2, stx2, hlyA, eae) strain was diagnosed in Oc-
tober–November. The connecting factor between 
the patients was identified as day care food, but the 
source of infection remained unidentified. At the end 
of October, eight children were infected by the strain 
in question, and in November the infection was diag-
nosed in nine of these children’s family members. In 
connection with the epidemic, some 300 stool sam-
ples from asymptomatic day care children, day care 
personnel, close contacts of patients and people who 
had contacted basic health care due to symptoms 
were analysed for EHEC bacteria.
frozen strawberries the suspected source 
of a nordic epidemic of hepatitis a
In January–October, 11 cases of hepatitis A were di-
agnosed in different parts of Finland and the virus 
type 1B was detected in the related serum samples. 
The affected persons had not travelled abroad prior 
to the occurrence of their symptoms. A virus of the 
same genotype was also identified in Denmark, Nor-
way and Sweden. Moreover, five 5 IgM positive cases 
of hepatitis A were detected, but their samples could 
not be genotyped. On the basis of a pan-Nordic case-
control study, frozen strawberries were the most like-
ly source of infection. However, the hepatitis A virus 
was not found in the strawberries and their origin has 
yet to be verified. In order to prevent infections, a 
recommendation was issued that frozen berries of for-
eign origin be heated.
recurrent epidemics caused by a new type 
of norovirus in espoo
In May–June, more than 170 people among ten 
groups of customers contracted gastroenteritis after 
visiting a hotel in Espoo. The patients’ symptoms, the 
incubation period of the disease and its duration were 
indicative of a norovirus epidemic but, using stand-
ard diagnostic methods, no norovirus could be found 
in the patient samples. Further analyses by the Na-
tional Institute for Health and Welfare revealed that 
the samples contained a norovirus belonging to geno-
group 1. Thereafter, the same type of virus was found 
in a repeat analysis of a water sample taken in May, 
and surface cleanliness samples taken in June in the 
hotel dining room toilet facilities. The epidemic was 
controlled by cleaning and disinfecting the house-
hold water supply system and enhanced cleaning of 
the hotel premises.
salmonella clusters
In June, S. Enteritidis FT 3, susceptible to antimicro-
bials, caused six cases in Eastern Finland, connected 
to travel in Russia and identical in genotype (MLVA 
3-2-7-10-2, SENT 15). The health authorities of the 
Republic of Karelia were informed of the cases.
In October, salmonella was detected in cattle suffer-
ing from diarrhoea on a farm in Western Finland. 
The people living on the farm, and the families to 
whom non-pasteurised milk had been sold by the 
farm, were examined in case of salmonella infection. 
S. Typhimurium FT135, susceptible to antimicro-
bials, was detected in eight persons, one of whom 
showed symptoms, and in the cattle faeces. An MLVA 
2-14-11-11-0312, STYM 245 strain, identical to the 
strains detected in the people who were tested, was 
identified in the farm environment and the cat living 
on the farm.
In October-November, (ACSSuT) S. Typhimurium 
FT 120, resistant to antimicrobials, caused a cluster 
of infections, with ten cases being diagnosed in differ-
ent parts of Finland. The strains in this cluster com-
prised two highly similar genotypes (MLVA 3-15-14-
23-0311 and 3-15-14-23-0110). A strain similar in 
susceptibility and phage type was detected in a strain 
isolated from German pork but an MLVA analysis 
indicated that it was different from the strains identi-
fied in the patients.
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Figures 6a and 6b. Cases of Clostridium difficile by hospital district, 2008–2013 (no. of cases).
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In October–December, eight cases caused by 
monophasic S. Typhimurium FT U311 strains were 
detected in nursing home units situated in differ-
ent localities. Identical strains (MLVA 3-13-11-NA-
0211, resistance profile ASSuT) were also detected in 
Norway and Sweden. Analyses are still underway.
clostridium difficilE
Clostridium difficile has been a finding reportable to 
the NIDR from the beginning of 2008. In 2013, 
almost 6,000 cases were reported (2012: >6,000, 
2011: >6,000, 2010: >6,000, 2009: >7,000, 2008: 
>8,000), of which 4,855 (2012: 5,256, 2011: 5,382, 
2010: 4,804, 2009: 5,700, 2008: 6,301) involved a 
toxin-producing strain. Almost 60% of the patients 
diagnosed with C. difficile were women, and about 
half were 75 years of age or older. A total of 183 
(4%) cases of toxin-positive strains were reported 
in those under the age of 15 (2008−2012: 2–3%). 
There were notable regional differences in incidence 
(32−206/100,000), which was highest in the Central 
Ostrobothnia, Lapland, Kymenlaakso and North Os-
trobothnia Hospital Districts.
The C. difficile bacterial strains typed at the National 
Institute for Health and Welfare originated in nine 
different hospital districts and covered 4% of the 
number of cases of infectious diseases reported. The 
strains were heterogeneous, and 58 different ribotypes 
were found. The submitting laboratory found that a 
considerable share (22%) of the typed strains had a 
potentially hypervirulent toxine gene profile (toxine 
A/B+, binary toxine+, tcdC deletion); these strains 
represented 23 different ribotypes, of which 078, 
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023, 027 and 126 were the most common. For the 
first time, ribotype 078 was the most common (11% 
of strains), while the share of ribotype 027 was 9.7% 
(2012: 4.3%). Other common ribotypes included 
023, 002, 020, 014, 001 and 005. Typing focused 
on severe cases and suspected epidemics. Background 
data indicates that 2.6% of the strains were related to 
severe cases, 15% to recurring infections and 16% to 
suspected epidemics.
EntErohaEmorrhagic 
EschErichia coli (EhEc)
A total of 98 microbiologically confirmed cases caused 
by enterohaemorrhagic Escherichia coli (EHEC) were 
reported to the NIDR (1.8/100,000). The number of 
infections tripled from 2012, when 30 infections were 
detected (0.6/ 100 000). In previous occasions in the 
2000s, the annual incidence of EHEC cases has been 
low in Finland (0.2−0.6/ 100,000) but in 2013, more 
than half of infections (61; 59%) were deemed to be 
of domestic origin. The incidence was highest in un-
der 5-year-olds (10.5/100,000). Haemolytic-uremic 
syndrome was diagnosed in 13 cases (13%).
A total of 17 of the cases were connected to the EHEC 
O157:H7 (stx2, eae, hlyA)  epidemic diagnosed in day 
care centres and schools in Lohja. A central kitchen 
was the connecting factor between the day care cen-
tres and schools in which the cases were diagnosed. 
Moreover, in the spring and towards the end of the 
year, a total of 16 cases caused by a sorbitol ferment-
ing EHEC O157:H7 (stx2, eae,hlyA) strain were di-
agnosed in different parts of Finland. According to 
interviews, seven patients had been in contact with a 
farm, and an EHEC strain identical with the patient 
strains was found on two farms. In addition, a family 
epidemic, probably connected to a farm, was detected 
in December, with an EHEC O157:H7 (stx1, stx2, 
eae, hlyA, PFGE 1.164) infection being diagnosed in 
five family members. The same EHEC strain was de-
tected on a farm where a family member, in whom 
EHEC was not found and who did not exhibit any 
symptoms, had worked at the end of November.
A bacterial culture for a total of 98 EHEC cases was 
confirmed by a laboratory. Of these, seven (7%) could 
only be confirmed using the PCR method, while the 
bacterial strain was isolated for others. Of the infec-
tions, 65 were acquired in Finland and 33 abroad. 
Strains of serotype O157:H7 caused a total of 58 cas-
es. They were divided into eight phage types, the most 
common being FT 8 (33%), FT 2 (29%) and FT 88 
(28%). All FT 88 strains were connected to two do-
mestic clusters that occurred on separate occasions, 
in the spring and towards the end of the year; were 
positive with regard to the stx2 gene; were sorbitol-
fermenting; were immobile despite the gene coding 
for a H7 flagella antigen; and, with the exception of 
one strain, were identical in PFGE genotype (1.203). 
All FT 2 strains were connected to the epidemic in 
Lohja, were positive with regard to the stx2 gene, were 
not sorbitol-fermenting, and, with the exception of 
one strain, were identical in PFGE genotype (1.211). 
There were 33 cases of serogroup Non-O157. The 
strains isolated from them comprised 12 different 
non-O157 serotypes. Serotype O26 was the most 
common (11 strains), comprising 5 different PFGE 
genotypes in turn. Two strains remained untyped 
(ONT) and one lacked the O antigen (O rough).
campylobactEr
In 2013, 4,064 findings of campylobacter were re-
ported, slightly fewer than in previous years, but 
campylobacter remains the most common bacte-
rial cause of gastrointestinal infections in Finland. 
Campylobacter jejuni remained the single most com-
mon type of campylobacter (2,448 cases); there were 
180 reported cases of C. coli, and 1,436 cases in whose 
case the campylobacter type was not specified.
The incidence in the entire population was 
75/100,000. Men accounted for 52% of the cases. 
The highest number of cases was reported in the age 
group 20 to 54 (incidence over 100/100,000). Inci-
dence was highest in the hospital district of Helsinki 
and Uusimaa (112/100,000).
The seasonal variation was typical of campylobacter: 
the incidence was highest in July–August (Figure 7). 
Of the cases in 2013, 478 (12 %) were domestic in 
origin, although 38 % of the cases lacked data on the 
country of acquisition. Foreign travel was a factor in 
50% (2,032) of the cases; the most common source 
being Spain (302), followed by Thailand (287) and 
Turkey (285).
listEria
In 2013, a total of 61 severe systemic infections caused 
by Listeria monocytogenes bacterium were diagnosed 
(2000−2011: 18–71, 2012: 62). About half of the pa-
tients were over the age of 75; men and women were 
equally represented. The listeria cases were spread out 
across the country. As yet, information on pregnancy 
is not reported to the National Infectious Diseases 
Register, but one case of listeriosis was diagnosed in 
a newborn baby on the basis of laboratory referrals. 
Upon the introduction of electronic notification of 
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Figure 7. Salmonella and campylobacter cases by month, 2002–2013 (no. of cases).
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Table 1. The most common serotypes of salmonella cases, 2002–2013 (excluding S. Typhi and S. Paratyphi) (no. 
of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Infection acquired abroad (source: nIdr)
Salmonella Enteritidis 904 887 758 834 879 735 1066 657 778 612 480 521
Salmonella group B 33 23 37 38 55 93 166 119 103 144 143 170
Salmonella Stanley 65 67 105 113 116 175 136 111 98 68 98 69
Salmonella Typhimurium 115 155 183 194 141 246 198 166 142 80 92 79
Salmonella Infantis 20 16 33 39 31 54 31 42 42 31 46 37
Salmonella Corvallis 10 40 39 60 56 59 70 68 42 45 42 35
Salmonella Virchow 55 67 74 88 80 135 115 90 77 35 30 29
Salmonella Newport 47 40 53 47 66 57 76 54 54 32 30 27
Salmonella Oranienburg 5 7 11 5 10 9 13 2 14 41 27 24
Salmonella Agona 29 21 26 23 25 20 33 22 25 23 30 23
Other 561 539 521 504 524 690 702 608 655 503 658 973
total 1844 1862 1840 1945 2027 2273 2606 1939 2030 1614 1676 1987
domestically acquired infections (source: bacteriology unit)
Salmonella Typhimurium 222 137 132 241 170 150 80 134 132 94 98 94
Salmonella Enteritidis 42 61 81 75 69 61 49 48 44 47 83 46
Salmonella group B 3 2 7 1 4 11 5 7 8 40 35 38
Salmonella Infantis 4 4 4 11 6 3 7 2 9 10 36 12
Salmonella Agona 16 12 27 32 11 40 15 2 2 11 33 12
Salmonella Newport 3 16 8 3 9 23 70 9 8 6 7 11
Salmonella Thompson 0 2 2 2 3 0 3 2 12 2 5 9
Salmonella Abony 15 7 7 2 0 0 2 2 8 4 16 7
Salmonella Napoli 0 3 2 0 2 0 2 0 6 6 3 7
Salmonella Corvallis 0 3 0 1 1 1 2 2 3 1 2 6
Other 101 63 66 75 122 83 139 101 102 117 89 95
total 406 310 336 443 397 372 374 309 334 338 407 337
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infectious diseases by physicians, surveillance data for 
listeriosis will also be specified.
A total of 61 strains of Listeria monocytogenes, isolated 
from the patient’s blood and/or cerebrospinal fluid, 
arrived for typing at a laboratory. The PCR method 
was used for determining the Listeria monocytogenes 
serotype. It was found that 47 (77%) of the strains 
typed were of serotype IIa (corresponding to serotype 
1/2a and 3a when using the earlier method) and 14 
(23%) were of serotype IVb (4b, 4d and 4e). These 
strains were divided into 38 PFGE genotypes. Typ-
ings revealed five domestic clusters of 3-4 strains (Asc 
218-Apa 30, Asc 14-Apa 5, Asc 96-Apa 1, Asc 440-
Apa 56, Asc 225-Apa 61), whose profiles were com-
pared with Evira’s database. Asc 218-Apa 30 strains 
were found in prepared salads and frozen mixes of 
peas, corn and paprika, while Asc 14-Apa 5 strains 
were found in salt-cured fish.
In 2013, up-to-date DNA typing data of L. monocy-
togenes strains was sent to the international database 
coordinated by the ECDC. So far, four international 
clusters that include DNA profiles of Finns have been 
found in the database. One strain is still being exam-
ined.
salmonElla
In 2013, a total of 1,987 salmonella cases were re-
ported (2012: 2,194), of which 55 per cent were 
detected in women. Annual incidence in the en-
tire country was 40/100,000 population. The inci-
dence was highest in the Hospital District of Lapland 
(54/100,000) and lowest in Åland (21/100,000). The 
highest number of infections was reported in the 20 
to 24 age group.
Nine cases of the S. Typhi bacterium, which causes 
typhoid, were identified. No information was avail-
able on a recent trip abroad in the case of two of the 
patients. One had arrived from India more than six 
months previously, while others had travelled in In-
dia, Nepal, Thailand or Kenya. Three cases were di-
agnosed of S. Paratyphi, which causes paratyphoid 
fever; two cases of S. Paratyphi B originated in Brazil 
and Bulgaria, and one S. Paratyphi A case originated 
in India.
Bacterial strains from a total of 1,777 cases of salmo-
nella were typed at the National Institute for Health 
and Welfare: 1,413 (79%) were of foreign and 337 
(19%) of domestic origin. The numbers of both do-
mestic and foreign cases fell slightly over the previous 
year. The incidence of Salmonella infections contract-
ed in the home country was 6.2/100,000 (in 2012: 
7.5/100,000). In 27 (2%) cases, the origin of the sal-
monella infection remained unclear.
Domestic salmonella infections were caused by 60 
different serotypes. The five most common includ-
ed Typhimurium (94/337, 28%), Enteritidis (46), 
group B (38), Agona (12), Infantis (12) and New-
port (11). Most (195/337, 58%) cases were still sus-
ceptible to all 12 antibiotics tested, but the share of 
multiresistants clearly rose compared to the previ-
ous year (2013: 70/337, 21% vs. 2012: 16%). The 
number of domestic cases in group B (38) is high 
for the third consecutive year. This increase is due to 
the monophasic S. Typhimurium of group B becom-
ing more common. Most monophasic Typhimurium 
strains were multiresistant (87%); most commonly 
to ampicillin, streptomycin, sulfonamide and tetra-
cycline. The most common phage type of monopha-
sics has varied; in 2011 it was FT 195, in 2012 FT 
193 and in 2013 FT 195 again, but the majority re-
mained untyped for phages or the phage type was un-
named (NT or NST). The multiresistant monophasic 
Typhimurium strain (FT U311, MLVA 3-13-11-NA-
0211) also caused an epidemic whose source remains 
unclear for the time being. Multiresistant FT 193, 
FT 195 and FT U311 strains are not known to occur 
in domestic production animals. Of other domestic 
strains of Typhimurium, 23% (22/94) were multire-
sistant. The traditional indigenous FT 1 phage type 
remained most common and its share is higher than 
in the previous year, but lower than a few years ago 
(2013: 27%, 2012: 23% and 2011: 60%). All FT 1 
strains were susceptible to antimicrobials and divided 
into seven MLVA genotypes, of which, as in previous 
years, 3-16-NA-NA-0311 was the most common. 
Unspecified phage types that caused a reaction (FT 
NST, not specific type) were found in 14% of cases, 
as was phage type 120 (14%). The usual number of 
cases were caused by the domestic Enteritidis serotype 
(46). These were mainly susceptible to antimicrobials 
(33/46, 71%) and were divided between 12 differ-
ent phage types. NT and NST strains accounted for 
11% of cases. A total of 17 different PFGE genotypes 
were found in all, the most common being SENT 
115 (65%), which was divided between four phage 
types and four MLVA types.
The salmonella infections acquired abroad repre-
sented 112 serotypes. The most common serotypes 
were the same as in two previous years: Enteritidis 
(479/1,413, 34%), Group B (158), Stanley (74) and 
Typhimurium (60). A total of 72% (383/532) of 
the strains originating in WHO/European countries 
(56 countries in Europe and the neighbouring areas) 
were of the Enteritidis serotype. An equal number 
of Enteritidis (16%, 126/811) and group B (15 %, 
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124/811) strains were brought in from outside the 
WHO/European countries. One half (705/1413) 
of the foreign strains were selected for antimicrobial 
susceptibility testing and further typing according 
to serotype. Selection focussed on strains originat-
ing in WHO/European countries, but was random 
with regard to serotype. The share of multiresistant 
strains had increased over the previous year, both 
in the WHO/European area (2013: 11% vs. 2012: 
8%) and outside it (28% vs. 24%). Enteritidis strains 
originating in the WHO/European countries were 
divided into 21 phage types; 55% were of the phage 
type FT 14b or FT 8, whereas the Enteritidis strains 
of far-off countries were more evenly divided into 14 
phage types. The group B strains (N=40) chosen for 
further typing and originating in far-off countries 
(most commonly Thailand) were mainly multiresist-
ant monophasic S. Typhimurium strains (N=33). The 
most common phage type was FT 195 (N= 20).
shigElla
In 2013, the incidence of shigellosis was 2.0/100,000. 
There were 110 reported cases, 51 in men and 59 in 
women. The median age in these cases was 35.5 years 
(variation 2–75). The majority of cases (77) were de-
tected in individuals aged 20−59. More than half of 
the cases (59) were reported in the Helsinki and Uusi-
maa Hospital District. Seven hospital districts had no 
diagnosed cases. The lack of findings in so many hos-
pital districts may well be indicative of problems in 
the primary diagnostics of shigella, which is known 
to require a high level of meticulousness when read-
ing samples. Of the total, 91 infections (83%) were 
reported as having been acquired abroad, ten were 
contracted in Finland and, in nine cases, the coun-
try of acquisition remained unspecified. The most 
common countries of origin were Egypt (21 cases) 
and India (16). The prevailing shigella species were 
Shigella sonnei (74 cases) and S. flexneri (30 cases). 
S. flexneri was divided into six different serotypes, of 
which serotype 2a caused a local cluster in Turku in 
February–March and serotype 3a was connected to 
travel in Egypt in April.
Of the 2013 strains, 79% (2012: 80%) were multire-
sistant (R to at least 4 out of 12 antimicrobials tested), 
and 43% were completely resistant or had reduced 
susceptibility to ciprofloxacin (MIC 0.125−12 mg/l) 
(2012: 45%). Some of the strains from Egypt were 
susceptible to ciprofloxacin, but this was not true of 
any of the strains isolated from infections acquired 
in India. Three strains were susceptible to cefotaxime 
(infections from Afghanistan, China and Vietnam).
yErsinia
Under the Communicable Diseases Decree, yersinia 
is among the bacteria that must be registered and re-
ported to the NIDR, but does not need to be sent 
to the strain collection of the National Institute for 
Health and Welfare. However, species typing and bi-
otyping/serotyping yersinia strains may pose a prob-
lem for clinical microbiology laboratories. Since the 
beginning of 2014, even problematic strains have not 
been routinely accepted.
yersinia enterocolitica
In 2013, the NIDR received 497 reports of Yersinia 
enterocolitica, the same as in 2012 (497). The inci-
dence for the entire country was 9.2/100,000. Based 
on the cases recorded in the NIDR, the incidence was 
highest in the over 75 age group (15/100,000) and 
lowest in the under 20 age groups. There was great 
regional variation in the Y. enterocolitica findings, the 
incidence being highest in the Helsinki and Uusimaa, 
North Ostrobothnia and Kymenlaakso Hospital Dis-
tricts (16/100,000) and in the Länsi-Pohja Hospital 
District (15/100,000), while no cases were found in 
the Hospital District of Itä-Savo.
Y. enterocolitica is most commonly confirmed from 
a stool culture. In 2013, stool cultures were used for 
confirming 436 cases, while only 60 cases were con-
firmed by antibody findings in serum; in one case, 
both antibody typing and a stool culture were used. 
Since Y. enterocolitica typing results were reported for 
less than 50% of the cases confirmed using a stool 
culture, no conclusions can be drawn regarding the 
share of different bio/serotypes or the actual clinical 
significance of the findings. Of the 88 Y. enterocol-
itica strains submitted to the National Institute for 
Health and Welfare for typing, one half (51%) were 
of the biotype 1A. Y. enterocolitica strains of biotype 
1A are a highly heterogeneous group of strains lack-
ing the pYV virulence plasmid typical of pathogenic 
yersinias. Therefore the biotype 1A strains are con-
sidered non-pathogenic. However, some strains may 
have other properties affecting their pathogenic capa-
bilities. A separate study found that Y. enterocolitica 
bacteria isolated from elderly patients in particular 
tend to be biotype 1A strains, while the pathogenic 
strains of bio/serotypes BT2/O:9 and BT3-4/O:3 are 
over-represented in small children.
yersinia pseudotuberculosis
The number of Yersinia pseudotuberculosis cases (39) 
was lower than in the previous year (56). The major-
ity of cases (33) were confirmed by culture and only 
6 by antibody findings. In 2013, the incidence in 
20
Report 18/2014
National Institute for Health and Welfare
Infectious Diseases in Finland 2013
Figure 8. Cases of norovirus infection per month, 2005–2013 (no. of cases).
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Figure 9. Rotavirus cases by age group in children aged 0 to 4, 2005–2013 (no. of cases).
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the entire country was 0.7/100,000 population. The 
number of cases is too low to indicate any regional 
variation, and 12 hospital districts diagnosed no cas-
es at all in 2013. In previous years, epidemics have 
caused high variation in the annual incidence of Y. 
pseudotuberculosis cases.
norovirus
In 2013, 2,296 cases of norovirus were reported, ap-
proximately 30% more than in 2012. Of these cas-
es, 89% were reported in January−May and 1,281 
(56%) in women. Although more than half (56%) of 
the patients were over 75 years of age, infections were 
diagnosed in all age groups. Cases were reported in all 
hospital districts.
The year 2013 was the sixth year running in which 
new variants of the norovirus GII.4 genotype, which 
emerge every one or two years, caused a widespread 
epidemic in Finland, as they did elsewhere in the 
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world. As in previous years (2007−2012), most of the 
epidemics that occurred in 2013 were institutional 
epidemics. This partly explains the high incidence 
among the elderly.
In 2013, epidemics were often caused by variants of 
norovirus GII.4 (GII.P4 Sydney 2012 or New Orle-
ans 2009 or a variant formed due to the recombina-
tion of either of these). Individual epidemics caused 
by other genotypes (e.g. GI.Pb, GII.Pb, GII.P7) also 
occurred in 2013.
Norovirus has become one of the most common caus-
es of food- or water-borne epidemics in the 2000s. In 
2013, food-borne epidemics were caused by norovi-
ruses of both genogroup I and genogroup II.
In May-June, a norovirus from genogroup I caused a 
major water-borne norovirus epidemic in a hotel in 
Espoo. The pathogen virus proved to be exceptional, 
as it was only found in further tests performed after 
ordinary diagnostics (for a more detailed description, 
please see the chapter Epidemics).
rotavirus
In 2013, 282 cases of rotavirus were reported. This 
is equivalent to the levels for 2011 and 2012. In re-
cent years, the quantity of rotaviruses has been clearly 
lower than in 2006. Rotavirus vaccines began to be 
supplied by pharmacies in summer 2006. The vac-
cine was initially underused, but by 2008 one child 
in three was receiving a rotavirus vaccination, paid 
for by the parents. The rotavirus vaccine was finally 
added to the national vaccination programme in Sep-
tember 2009.
The highest incidence by far again occurred in the 
under 5 age group (44/100,000), but this was clearly 
lower than the average incidence before the vaccina-
tion programme (460/100,000 in this age group). 
With increasing vaccination of infants, the percent-
age of cases in older age groups will increase. In 2013, 
52% of all cases occurred in patients aged 5 or over, 
whereas this figure had never been higher than around 
10% in previous years.
The illnesses caused by the various serotypes are very 
similar. Rotavirus diagnoses are mainly based on 
quick tests that do not indicate the type of virus. In 
2013, cases were caused by rotavirus types G1P[8], 
G2P[4], G3P[8], G4P[8], G9P[8] and G12P[8].
Thanks to the rotavirus vaccination programme, vac-
cination coverage is high. An investigation is ongoing 
into whether the number of virus strains reduced due 
to vaccination or strains already destroyed are gradu-
ally being replaced by others. Rotaviruses were there-
fore included in microbial strain collection in accord-
ance with the Communicable Diseases Act and De-
cree on 1 May 2013. This means that all faeces that 
tested positive in quick tests are sent to the virology 
unit of the National Institute for Health and Welfare 
for molecule genetic typing.
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Hepatitis
The number of hepatitis A cases was five times higher year-on-year. The • 
exceptionally high number of cases was due to an epidemic that spread via frozen 
berries.
Very few acute hepatitis B infections were reported.• 
Hepatitis C infections were most prevalent in the 20 to 29 age group. Half of the • 
infected patients in all age groups were intravenous drug users.
hEpatitis a
In 2013, 41 cases of hepatitis A (0.8/100,000) were 
reported, five times more than in the previous year. 
The patients were equally divided, 22 men and 19 
women. The median age in these cases was 25 years 
(variation 0–77). Cases of hepatitis A were found in 
11 hospital districts, the highest number of being 
identified (20) in the Hospital District of Helsinki 
and Uusimaa and the second highest in the Hospi-
tal District of Vaasa (7). Of the infections, 20 were 
acquired in Finland and 12 abroad, while the loca-
tion of infection was not reported for nine cases. The 
exceptionally high number of cases in comparison 
with previous years, and the high share of infections 
acquired in Finland was due to the fact that the epi-
demic spread through frozen berries. This epidemic 
caused cases not only in Finland, but also in other 
Nordic countries (see food-borne epidemics p. 13).
hEpatitis b
In 2013, 20 acute hepatitis B infections were report-
ed (0.4/100,000), 13 in men and seven in women. 
Sixteen of the infected patients were Finnish. The 
mode of transmission was known in 11 cases, being 
sexual contact in all but one. The country of acqui-
sition was reported in 12 cases – six infections had 
been acquired in Finland, six abroad.
Today, the number of acute hepatitis B infections re-
ported is significantly lower than in the late 1990s 
when, at most, over 200 infections were identified 
each year. This decrease is mainly due to higher vac-
cination coverage. Moreover, needle exchange has re-
duced the number of infections among users of in-
travenous drugs. Vaccination of risk groups began in 
the 1990s. The vaccine has been popular, particularly 
among travellers.
The number of chronic hepatitis B infections report-
ed was 247 (4.6/100,000), 58% in men and 42% in 
women. The majority, 85% of infections, were diag-
nosed in foreigners. The mode of transmission was 
reported in only 16% of cases, with perinatal infec-
tions and infections due to sexual contact being most 
common.
The number of cases of chronic hepatitis B has de-
creased since it peaked at over 600 in 1996. However, 
this decrease has not been as sharp as that of the acute 
cases, probably due to the high share of foreigners.
The division of hepatitis B cases between acute and 
chronic cases has been specified: only cases in which 
the laboratory reports IgM antibodies (S-HBc-AbM) 
are presently classified as acute. The statistics for the 
years 2008−2013 have been amended, resulting in 
figures which differ from those previously reported.
hEpatitis c
In 2013, 1,172 new cases of hepatitis C were report-
ed to the NIDR (22/100,000), 66% of the patients 
being men and 34% women. The highest number of 
infections, 44% in all, were reported in the 20−29 
age group. In this age group, infections have become 
slightly more common in recent years. In approxi-
mately one half of the cases, the reported method of 
transmission was intravenous drug use, in seven per 
cent sexual contact and for almost 40% of the cases 
the method of transmission was not reported.
The majority (83%) of hepatitis C infections were 
found in Finnish patients. The country of acquisition 
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Figure 10. Hepatitis C by age group, 2002–2013 (no. of cases).
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Table 2. All cases of hepatitis C according to physicians’ reports, by transmission routes, 2002–2013 (no. of 
cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Injecting drugs 717 637 615 629 578 468 574 516 596 600 615 607
Sex 45 46 60 62 72 68 74 70 73 86 69 85
Perinatal 3 1 11 5 5 3 11 9 10 11 7 3
Blood products 19 22 18 24 7 21 20 2 9 7 7 9
Other 28 35 31 34 37 28 34 31 38 39 31 37
Unknown 560 524 506 490 469 577 429 422 406 417 450 445
total 1372 1265 1241 1244 1168 1165 1142 1050 1132 1160 1179 1186
was known in 60% of the cases. In 85% of the cases 
where the country of acquisition was known, the in-
fection was contracted in Finland. The highest inci-
dences in relation to population were reported in the 
hospital districts of Länsi-Pohja (39/100,000) and 
South Karelia (38/100,000) and the lowest in North 
Ostrobothnia (6/100,000) and Central Ostrobothnia 
(7/100,000).
The majority of hepatitis C infections were reported 
without an identity number until 1998. The high fig-
ures of hepatitis C in the late 1990s and early 2000s 
(1,400−1,900 cases) are due to changed reporting 
practices and cases reported in previous years be-
ing recorded as new ones. Since 2006, the annual 
number of cases has remained below 1,200, being at 
its lowest in 2009 (1,042) and increasing to close to 
1,200 since then.
A very high percentage, around 80%, of intravenous 
drug users have been found to have hepatitis C an-
tibodies. Because of this, it is difficult to reduce the 
incidence of hepatitis C virus further among intrave-
nous drug users, despite needle and syringe exchange 
programmes.
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Figure 11. Incidence of hepatitis C in Finland in 2013, no. of cases per population of 100,000.
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Sexually transmitted diseases
Almost one half of gonorrhoea infections were contracted abroad, mainly in • 
Thailand.
More than one in three gonorrhoea infections were contracted through sexual • 
contact between men.
The number of HIV infections has not changed significantly in recent years. • 
In addition, the number of AIDS cases and that of deaths from AIDS remained 
unchanged.
Figure 12. Chlamydia cases in the young adult age groups, 2002–2013 (no. of cases).
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chlamydia (chlamydia 
trachomatis)
A total of 13,216 cases of chlamydia were reported 
(244/100,000), less than in 2012; 59% of the patients 
were women. The highest incidence was found in the 
Hospital Districts of Lapland (286/100,000), Hel-
sinki and Uusimaa (285/100,000) and Päijät-Häme 
(283/100,000). The incidence was highest (42%) in 
women and men aged 20–24. Patients under the age 
of 20 accounted for 30% of the women (2,299) and 
13% of the men (677).
Since 2011, cases of lymphogranuloma venereum 
(LGV) caused by Chlamydia trachomatis L1-3 immu-
notypes have been reported. In 2013, seven men were 
diagnosed with LGV.
gonorrhoEa (nEissEria 
gonorrhoEaE)
Fewer gonorrhoea infections were reported than in 
the previous year: 268 cases (4.9/100,000). Of these, 
74 per cent were diagnosed in men. Most infections 
were found in the 20 to 24 age group, both in women 
(30%) and men (20%). The mode of transmission 
was reported in 81 per cent of cases, and 35 per cent 
of the infections in men were contracted through 
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Finland 100 89 133 133 112 79 90 115 123 106 164 154
Thailand 31 27 38 30 42 44 34 36 45 35 35 31
Estonia 5 2 6 1 0 2 0 0 3 8 6 0
Russia 28 9 7 23 12 6 17 8 8 6 7 3
Other 18 21 21 20 25 22 24 40 33 41 55 49
Unknown 53 41 47 33 45 42 35 40 45 92 45 31
total 235 189 252 240 236 195 200 239 257 288 312 268
Table 3. Gonorrhoea infections acquired domestically and abroad, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Finland 25 30 22 25 21 56 57 69 36 29 55 25
Russia 22 18 16 22 18 17 26 18 26 22 27 22
Thailand 0 1 2 1 1 2 6 5 4 5 6 5
Estonia 1 6 1 6 3 4 9 3 9 4 6 4
Other 14 16 12 21 20 29 43 40 50 45 41 28
Unknown 67 62 58 68 67 79 75 67 84 74 66 72
total 129 133 111 143 130 187 216 202 209 179 201 156
Table 4. Syphilis infections acquired domestically and abroad, 2002–2013 (no. of cases).
sexual contact between men. The incidence was high-
est in the hospital districts of Helsinki and Uusimaa 
(11/100,000), Pirkanmaa (4.3/100,000) and South-
west Finland (3.8/100,000). The country of acquisi-
tion was specified in 88% of cases; 56 per cent of 
these infections having been contracted in Finland. 
The most infections were acquired in Thailand (31 
cases).
In 2013, no Gonococcus strains resistant to cipro-
floxacin were diagnosed.
syphilis (trEponEma 
pallidum)
In 2012, the number of syphilis cases reported to-
talled 157 (2.9/100,000), fewer than in 2012 (200). 
Men accounted for 64% of the cases, the number of 
infections being highest (15%) for men in the 40−44 
age group and women (29%) in the 30−34 age 
group. The mode of transmission was reported in 33 
per cent of cases, and one quarter of the infections in 
men were contracted through sexual contact between 
men. The incidence was highest in the hospital dis-
tricts of South Karelia (6.0/100,000), Helsinki and 
Uusimaa (5.4/100,000), and Lapland (4.2/100,000). 
The country of acquisition was specified in 54 per 
cent of cases; in 16 per cent of these, the infection 
had been acquired in Finland. Russia was the most 
common foreign country of acquisition (22).
hiv and aids
In 2013, 157 new HIV infections were diagnosed 
(incidence 2.9/100,000). In all, 16 cases of AIDS and 
eight deaths from AIDS were reported. No significant 
changes were found in infections, and the numbers of 
AIDS cases and deaths from AIDS also remained on 
a par with recent years.
Of the infections in 2013, 65% were diagnosed in 
men and 35% in women. The average age at the 
time of diagnosis was 39 years. The majority of in-
fections were acquired through sexual contact. For-
eigners accounted for 48% of all cases, of which 53% 
(5.8/100,000) were reported in the Hospital District 
of Helsinki and Uusimaa. The mode of transmission 
was unknown in 27% of cases, of which almost 80% 
were foreign. 
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Figure 13. HIV cases by transmission route, 2002–2013 (no. of cases).
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A total of 67 infections, or 54% of all cases, were re-
ported as having been contracted through heterosex-
ual contact. Foreigners accounted for 45% of the in-
fections and two in three infections were contracted 
abroad. Travel plays a key role in infections of Finns 
acquired through heterosexual contact.
A total of 43 infections, or 27% of all cases, were 
reported as having been contracted through sexual 
contact between men. Finns accounted for 93% of 
these cases, 39% of the infections having been ac-
quired abroad.
Only three cases were diagnosed in which the infec-
tion was acquired through intravenous drug use. In 
all of these cases, the infected person was a foreigner. 
The exchange of needles and syringes, and HIV med-
ication of infected patients have succeeded in keeping 
infections at a low level since the epidemic at the turn 
of the millennium.
One mother-child infection was reported. The child 
was born abroad. A total of 32 infections were de-
tected in maternity clinic screenings and seven of 
these were new. In the other cases, the infection was 
known about before pregnancy. In the 2000s, all but 
one mother-child transmission have been of foreign 
origin. Mother-child transmission can be effectively 
prevented with HIV medication during pregnancy.
No infections caused by a blood transfusion were re-
ported. There have been no reported cases of infec-
tion through blood products in Finland since HIV 
testing of donated blood began in 1985.
In 2013, 16 new cases of AIDS were reported, 12 in 
Finns and four in foreigners. The number of HIV-
positive patients who died during the year was 21, the 
cause of death being AIDS in eight cases. Medication 
begun early enough effectively prevents deaths from 
AIDS.
As in earlier years, the percentage of late detection of 
infections (CD4 lower than 350) was high, at 52%. 
Late diagnosis weakens the treatment prognosis and 
increases the possibility of further infections. Prelim-
inary analyses indicate that 4% of strain collection 
samples showed primary resistance mutations, at the 
same level as in the previous year.
By the end of 2013, the total number of HIV in-
fections reported in Finland was 3,219. The reported 
number of HIV positive patients who died is 584, the 
cause of death being AIDS in 313 cases.
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Antimicrobial resistance
The number of MRSA cases and blood culture findings remained unchanged in • 
comparison with previous years.
The number of VRE cases decreased.• 
The number of ESBL • E. coli findings continued to grow.
The majority of bacterial strains producing carbapenemase originated abroad.• 
mrsa
In 2013, 1,289 cases of methicillin-resistant Staphylo-
coccus aureus (MRSA) were reported, about the same 
number as in the year before (2012: 1283). Also, the 
number of MRSA cases diagnosed using a blood cul-
ture was the same as in the previous year (2013: 30 
and 2012: 30). Of these MRSA blood culture find-
ings, 9 (30%) were in the Pirkanmaa Hospital District 
(1.8/100,000) and 9 (30%) in the Hospital District 
of Helsinki and Uusimaa (0.6/100,000). The other 
hospital districts reported zero to three cases each, to-
talling 12. Most (19 out of 30) of the invasive cases 
occurred in patients older than 65, and none in chil-
dren. As earlier, the hospital districts of Pirkanmaa 
and of Helsinki and Uusimaa reported the highest 
total figures. The incidence was highest in the Pirkan-
maa and South Ostrobothnia Hospital Districts. The 
percentage of findings in patients aged over 75 was 
43, slightly more than before (37%). The number of 
MRSA cases in children did not increase (127-113).
The MRSA strain was typed in 1,330 individuals. 
There were 211 different spa types among the MRSA 
strains (2012: 186). The three most common spa types 
were the same as in the previous years. In 2013, the 
most common types were: t172 18% (2012: 17%), 
t067 16% (2012: 15%), t008 11% (2012: 12%), 
t032 4% (2012: 3%) and t044 3% (2012: 2%). t172 
was found in 18 hospital districts whereas t067 was 
detected in eight hospital districts, most commonly 
in Pirkanmaa and South Ostrobothnia. The incidence 
of the strain t067 increased markedly in the Hospital 
District of South Ostrobothnia in 2013.
Moreover, local clusters were caused among others by 
t020 and t509 in the Hospital District of Helsinki 
and Uusimaa, t721 and t304 in the Hospital District 
of North Karelia and t1012 in the Hospital District 
of Pirkanmaa.
The most common spa type among patients over 75 
was t067 (26%; 2012 27%). The most common spa 
types among children under the age of 16 were t172 
(18%), t044 (13%) and t019 (7%). In 2012 too, 
t172 was the most common spa type among children 
(18%), followed by t657 (9%) and t008 (8%).
An MRSA strain isolated from the blood was typed 
in 25 individuals. Five of these were of spa type t067, 
three of spa type t008, two of spa type t172 and the 
remainder (15/25) featured different spa types.
In 2013, three MRSA strains with the mecC gene 
were isolated from clinical samples in the Hospital 
District of Helsinki and Uusimaa, Pirkanmaa and 
North Savo. Two of the strains were of the spa type 
t843 and one t742. 
vrE
The number of reported cases of vancomycin-resist-
ant enterococcus (VRE) in 2013 decreased on the 
previous year (2013: 45 and 2012: 93). The most 
cases were reported by the hospital districts of Hel-
sinki and Uusimaa (17), North Ostrobothnia (7) and 
Central Ostrobothnia (7) (31/45) and in the over 
65 age group (30/45). In other hospital districts, the 
number of findings varied from zero to three. Nine of 
the findings were blood culture findings (2012: 7).
VRE strains were typed in 33 individuals. As in previ-
ous years, most of the findings represented the E. fae-
cium (28/33) species and the vanB type (22/33). The 
new epidemic strain VRE XIII, representing the E. 
faecalis species, which spread in 2012 in the Kymen-
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Figures 14a and 14b. MRSA cases by hospital district, 2002–2013 (no. of cases).
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laakso Hospital District, was only detected in one 
individual in 2013. Almost all of the typed strains 
were individual findings with a specific pulsed field 
gel electrophoresis (PFGE) profile (28/33). Only in-
dividual cases of the most common strain types that 
had caused clusters in the two previous years were 
found in 2013: VRE VII (1/33), VRE X (2/33) or 
VRE XI (1/33).
Esbl
Since the beginning of 2008, Escherichia coli and 
Klebsiella pneumoniae exhibiting reduced suscepti-
bility or resistance to third-generation cephalosporin 
(I for intermediate and R for resistant, respectively) 
have been reported to the NIDR. The majority of 
these bacteria are strains producing ESBL-entzyme 
that split penicillin and cephalosporins. 
In 2013, the majority of ESBL findings were E. coli 
(4,445; in 2012: 3,688) and a small minority of K. 
pneumoniae strains (255; in 2012: 204). E. coli ESBL 
findings were made in all age groups, 76% in wom-
en and over half in patients aged 65 years or more. 
One half of diagnoses (50%, 2,226 /4,445) were 
made based on urine. The largest number of cases 
was found in the Hospital District of Helsinki and 
Uusimaa (1,370, 89/100,000), but the incidence was 
highest in the Lapland (128/100,000), Kymenlaak-
so (104/100,000) and North Karelia (103/100,000) 
hospital districts and in Åland (162/100,000). The 
number of blood findings was slightly higher than in 
2012 (230 vs. 204) (the ESBL proportion in E. coli 
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all mrsa findings s. aureus blood culture  
findings
mrsa blood culture findings and the 
methicillin resistance of  s. aureus (%)
1995 89 627 2 (0,3)
1996 110 667 0 (0,0)
1997 121 747 4 (0,5)
1998 190 719 5 (0,7)
1999 212 813 8 (1,0)
2000 266 850 4 (0,5)
2001 340 887 4 (0,5)
2002 600 989 9 (0,9)
2003 859 981 7 (0,7)
2004 1478 1059 30 (2,8)
2005 1381 1013 27 (2,7)
2006 1330 1239 37 (3,0)
2007 1297 1179 32 (2,7)
2008 1772 1261 40 (3,2)
2009 1267 1288 30 (2,3)
2010 1267 1370 26 (1,9)
2011 1327 1487 42 (2,8)
2012 1283 1488 30 (2,0)
2013 1289 1595 30 (1,9)
Table 5. MRSA-findings and their percentage of S. aureus blood culture findings, 1995–2013 (no. of cases and 
%). 
esbl-findings e. coli blood culture findings esbl e. coli blood culture findings and 
percentage of esbl of e. coli
2008 1707 2813 42 (1,5)
2009 2158 2991 77 (2,6)
2010 2522 3211 112 (3,5)
2011 3119 3473 150 (4,3)
2012 3688 3448 204 (5,9)
2013 4445 3877 230 (5,9)
Table 6. E. coli findings with reduced susceptibility to third-generation cephalosporins (possible ESBL, extend-
ed-spectrum β-lactamase) and ESBL percentage, 2008–2013 (no. of cases and %).
blood cultures: 230/3,877, 5.9% vs. 5.9% in 2012). 
Of these, 25% were in the Hospital District of Hel-
sinki and Uusimaa. However, the incidence in blood 
culture findings was highest in the hospital district of 
Länsi-Pohja.
Over half of the ESBL cases reported that involved 
K. pneumoniae were also diagnosed in patients aged 
65 years or over, but the percentage of women was 
smaller than with E. coli, being 65%. More than one 
third of diagnoses (36%, 91/255) were made from 
urine. The largest number of cases was recorded in 
the hospital districts of Helsinki and Uusimaa (93) 
and North Ostrobothnia (26), while the incidence 
was highest in the hospital district of Lapland. Fifteen 
(2012: 17) of the findings were made from blood (the 
ESBL proportion in the K. pneumoniae -blood cul-
tures: 15/570, 2.6% vs. 2012: 2.9%).
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esbl findings K. pneumonia blood culture 
findings
esbl K. pneumoniae blood culture  
findings and percentage of  
esbl of K. pneumoniae
2008 111 418 4 (1)
2009 154 480 6 (1,3)
2010 184 504 16 (3,2)
2011 244 449 16 (3,6)
2012 204 581 17 (2,9)
2013 255 570 15 (2,6)
Table 7.  K. pneumoniae findings with reduced susceptibility to third generation cephalosporins (possible 
ESBL, extended-spectrum β-lactamase) and ESBL percentage, 2008–2013 (no. of cases and %).
cpe (carbapenemase-producing 
enterobacteria)
During 2013, 122 strains of Escherichia coli, Klebsiella 
pneumoniae and Enterobacter cloacae were examined 
for carbapenemase genes because of their reduced sus-
ceptibility to carbapenems. 21 of the strains studied 
had a carbapenemase gene and four strains of E. coli 
had an NDM gene. These strains were all of different 
sequence types (ST405, ST636, ST648 and ST940). 
In all cases, the patient had a contact with a foreign 
country (India, Croatia, Cambodia). Bacterial strains 
with NDM carbapenemase are common on the Indi-
an Peninsula and endemic in the Balkans region. Two 
E. coli strains were diagnosed with OXA-48 carbap-
enemase, and in both cases the patients had a contact 
with a foreign country (Holland and Turkey). Four-
teen strains of K. pneumoniae studied had a carbapen-
emase gene: two of them NDM, one OXA-48 and 11 
KPC. The figures include ten K. pneumoniae strains 
resistant to carbapenems, isolated from a local epi-
demic and all found to have the KPC carbapenemase 
gene. The strains with the NDM gene were of the se-
quence type ST 231 and ST 11 and the patients had 
a contact with a foreign country (Thailand, India). 
Also, the OXA-48 positive strain was of the sequence 
type ST11 and the patient had received treatment in 
a hospital in Spain. The strains with the KPC gene 
were all of the sequence type ST512, which has not 
previously been found in Finland. It is related to and 
is believed to have originated from the K. pneumoniae 
ST258 strain, which is widespread around the world. 
The K. pneumoniae ST512 strain is known to have 
caused hospital epidemics in Israel and Italy. Patients 
diagnosed with these K. pneumoniae ST512 strains 
have had no contacts with foreign countries. In 2013, 
one strain of E. cloacae had KPC carbapenemase. 
Even in this case, the patient had a contact with a 
foreign country (Dominican Republic).
As in 2012, a major percentage of bacterial strains 
with carbapenemase were of foreign origin, but strains 
of Finnish origin were also found. In 2013, the first 
actual local epidemic was diagnosed in Finland. It 
should be noted that the bacterial strain that caused 
the epidemic was a sequence type, related to the high-
ly communicable K. pneumoniae strain, that has been 
rare until now. Moreover, infection by these K. pneu-
moniae strains most probably occurred in Finland.
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Tuberculosis
One third of patients contracting tuberculosis were foreigners and most of the • 
patients were aged between 15 and 44.
Almost all • M. tuberculosis strains were susceptible to drugs.
Pulmonary tuberculosis treatment outcome surveillance for 2011 indicated that • 
treatment outcomes were good in 69 per cent of the cases. This figure is on a 
par with the figures of most EU countries.
tubErculosis 
(mycobactErium 
tubErculosis)
tuberculosis monitoring
Between 1995 and 2006, the registered tuberculosis 
cases included all cases confirmed by culture, as re-
ported by the laboratories. In addition, cases reported 
by a physician were only included if the diagnosis was 
based on histology or a case of pulmonary tubercu-
losis was confirmed by positive sputum staining for 
tuberculosis bacilli.
From 2007 onwards, following the definition of tu-
berculosis cases in EU infectious disease monitoring, 
the statistics include all cases where a physician sus-
pected tuberculosis on the basis of clinical evidence 
and decided to give full tuberculosis treatment even 
if the infection was not confirmed by microbiologi-
cal tests or histology. The new grounds for compiling 
statistics do not affect the number of cases confirmed 
by laboratory tests or histology.
Incidence of tuberculosis 2013
There were 269 cases of tuberculosis (5.0/100,000), 
six cases fewer (2%) than in 2012 (275, 5.1/100,000). 
Of these, 213 (79%) were pulmonary tuberculosis, of 
which 91 (43%) produced a positive sputum stain 
test. There were 204 cases of tuberculosis confirmed 
by culture (76%), 20 fewer than in 2012 (224). Ac-
cording to physicians’ reports, 17 patients (6%) had a 
previous history of tuberculosis diagnosed after 1950, 
when anti-tuberculosis medication became available.
The increase in the overall number of tuberculo-
sis cases in Finland in 2007 and 2008 compared to 
2006 can be explained by the introduction in 2007 
of the broader EU definition of tuberculosis cases. 
The annual numbers of cases confirmed by culture 
are comparable throughout the monitoring period. 
The number of these cases remained stable from 
2007 to 2011 except in 2009, when an exceptionally 
large number of cases in foreigners was recorded; in 
2012−2013, however, the figure was lower.
The distribution of cases by age group was as follows: 
under 15, 2 (1%); 15 to 29, 52 (19%); 30 to 44, 35 
(13%); 45 to 59, 30 (11%); 60 to 74, 65 (24%); and 
over 75, 83 (31%). In half of all cases the patients 
were over 60 years of age, and most of them were 
born in Finland; their cases involved a reactivation of 
a latent infection contracted decades ago. Population 
reduction among the age groups in whose youth the 
incidence of tuberculosis in Finland was high has led 
to a notable decrease in the average age of tuberculo-
sis patients between 2000 and 2013, from 64 to 57 
years. No increasing trend has been found in children 
aged under 5 after the change to the vaccination pro-
gramme in 2006.
The patient was reported to be foreign in 86 cases 
(32%), i.e. born abroad and assumed to have other 
than Finnish citizenship unless the data indicates oth-
erwise. The distribution of these cases by age group was 
as follows: under 15, none; 15 to 29, 45 (52%); 30 to 
44, 30 (35%); 45 to 59, 5 (6%); and over 60, 6 (7%). 
Among these there were 65 cases (76%) of pulmonary 
tuberculosis and 21 cases (24%) of other forms of tu-
berculosis. Information on the patient’s country of 
birth or citizenship was missing in 2 cases (1%).
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pulmonary tuberculosis other  
tuberculosis
all cases
cases cases 
/100,000
cases with 
positive 
sputum 
smear
cases with 
positive  
sputum 
smear 
/100,000
cases cases 
/100,000
cases cases 
/100,000
culture-
confirmed 
cases 
propor-
tion of 
culture-
confirmed 
cases (%)
1995 436 8,6 241 4,7 217 4,3 653 12,8 475 72,7
1996 442 8,6 232 4,5 193 3,8 635 12,4 513 80,8
1997 360 7,9 185 3,6 197 3,8 557 10,9 442 79,4
1998 397 7,7 203 3,9 213 4,1 610 11,9 494 81
1999 405 7,8 185 3,6 188 3,6 593 11,5 510 86
2000 376 7,3 227 4,4 171 3,3 547 10,6 460 84,1
2001 312 6 150 2,9 181 3,5 493 9,5 411 83,4
2002 299 5,8 136 2,6 175 3,4 474 9,1 392 82,7
2003 290 5,6 144 2,8 122 2,3 412 7,9 348 84,5
2004 233 4,5 128 2,5 103 2 336 6,4 291 86,6
2005 269 5,1 136 2,6 100 1,9 369 7 321 87
2006 212 4,0 101 1,9 83 1,6 295 5,6 270 91,5
2007 235 4,5 93 1,8 111 2,1 346 6,6 250 72,3
2008 222 4,2 109 2,1 124 2,3 346 6,5 247 71,4
2009 295 5,5 96 1,8 116 2,2 411 7,7 303 73,7
2010 242 4,5 88 1,6 83 1,5 325 6,0 258 79
2011 236 4,4 86 1,6 90 1,7 326 6,1 251 77
2012 196 3,6 83 1,5 79 1,5 275 5,1 224 81,5
2013 213 3,9 91 1,7 56 1,0 269 5,0 204 75,8
Table 8. Incidence of tuberculosis and percentage of culture-confirmed cases in Finland, 1995–2013 (no. of cases 
and %).
In four (2%) of the tuberculosis cases reported in 
2013, the patient also had an HIV infection. Two of 
these were new HIV infections reported in 2013, and 
two had been reported earlier. Two of the cases were 
foreign in origin.
tuberculosis genotyping findings 2013
All new Mycobacterium tuberculosis strains were geno-
typed using the internationally standardised spoligo-
typing and MIRU-VNTR methods. In 2008−2013, 
of the total of 1,474 M. tuberculosis strains typed, 578 
(39%) occurred in clusters.
The most common cluster in Finland is the Jazz clus-
ter (SIT42), which has been spreading in the Helsin-
ki metropolitan area for a long time. Four new cases 
were connected to this cluster in 2013. The second 
most common cluster is the SIT53, which is wide-
spread in Denmark and Sweden. Six new cases in dif-
ferent parts of Finland were connected to this clus-
ter. Four new cases emerged in the SIT53 cluster that 
had spread among socially marginalised people in the 
Tampere region. A total of twelve cases confirmed by 
culture were diagnosed in the epidemic that broke 
out in schools in Turku in 2012−2013 (the SIT149 
cluster). Two cases of laboratory contamination were 
diagnosed through genotyping.
tuberculosis strain susceptibility in 2013
The susceptibility of M. tuberculosis strains remains 
very good in Finland. Of all cultured strains, 95% 
had full susceptibility. Resistance to a drug was di-
agnosed in only ten cases. Two multi-drug resistant 
(MDR) cases were found during the year, both of 
Finnish origin.
tuberculosis outcome surveillance in 
2007−2011
Table 10 shows the distribution of treatment out-
comes between 2007 and 2011. The domain con-
sists of cases of pulmonary tuberculosis confirmed by 
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pulmonary tuberculosis other tuberculosis all cases
cases in  
foreigners
proportion 
of foreigners 
(%)
cases in  
foreigners
proportion 
of foreigners 
(%)
cases in  
foreigners
proportion 
of foreigners 
(%)
1995 25 5,7 13 6 38 5,8
1996 17 3,8 24 12,4 41 6,5
1997 23 6,4 23 11,7 46 8,3
1998 26 6,5 31 14,6 57 9,3
1999 25 6,2 21 11,2 46 7,8
2000 29 7,7 16 9,4 45 8,2
2001 34 10,9 28 15,5 62 12,6
2002 23 7,7 24 13,7 47 9,9
2003 36 12,4 13 10,7 49 11,9
2004 22 9,4 20 19,4 42 12,5
2005 28 10,4 24 24 52 14,1
2006 30 14,2 22 26,5 52 17,6
2007 45 19,1 28 25,2 73 21,1
2008 31 14 22 17,7 53 15,3
2009 81 27,4 43 37,1 124 30,1
2010 72 30 32 39 104 32
2011 49 20,8 31 34,4 80 24,5
2012 54 27,6 23 29,1 77 28,0
2013 65 30,5 21 37,5 86 32,0
Table 9. Cases of tuberculosis in foreigners, 1995–2013 (no. of cases and %).
culture, genetic replication (PCR) or mycobacterial 
staining. Cases where the pathogen is an MDR strain 
are reported separately and are not included in Table 
10. An outcome evaluation is performed 12 months 
after the sample is taken.
The treatment outcome was good in 69% of cases in 
2011. It falls clearly short of the international target 
set by the WHO at 85% but is on a par with the av-
erage for most EU Member States. Mortality (before 
beginning treatment or during treatment) was 19%.
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2007 2008 2009 2010 2011
Cases under surveillance 200 191 241 187 191
trEatmEnt outcomE
favourable 144 (72%) 140 (73%) 167 (69%) 149 (80%) 132 (69%)
Cured 85 89 84 94 74
Treatment completed 59 51 83 55 58
non-favourable 41 (21%) 37 (19%) 44 (18%) 22 (12%) 38 (20%)
Deceased 38 (19%) 33 (17%) 41 (17%) 18 (10%) 37 (19%)
Treatment failure 1 1 0 0 1
Interrupted treatment 2 3 3 4 0
missing 15 (7%) 14 (7%) 30 (12%) 16 (8%) 21 (11%)
Transfer 2 2 13 4 7
Treatment continues at 12 
months 7 9 9 8 8
Notified, as not known 1 3 2 1 5
Notification missing 5 0 6 3 1
Table 10. Results of outcome evaluation for treatment of microbiologically confirmed pulmonary tuberculo-
sis, 2007–2011 (no. of cases and %).
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Other infections
Only six cases of severe pneumococcal diseases caused by vaccine serotypes were • 
detected in under 2-year-olds. Of these, all but one were identified in unvaccinated 
children.
The percentage of penicillin-resistant strains and those with reduced susceptibility • 
began to decrease.
The number of meningococcus infections decreased by one third in comparison • 
with the three previous years.
Only two cases of meningococcus were reported.• 
The occurrence of borrelia has not increased in comparison with previous years.• 
The number of tick-borne encephalitis (TBE) cases remained unchanged in • 
comparison with previous years.  Most cases of TBE were diagnosed in September.
Approximately 50 per cent more cases of Puumala virus were reported than in • 
2012. The majority of patients were of working age.
A total of 50 people were exposed to rabies abroad, mainly in Thailand and Russia. • 
More than half of these were related to dog bites.
invasivE pnEumococcal 
disEasE (strEptococcus 
pnEumoniaE)
A total of 724 cases (13/100,000) of invasive pneu-
mococcal disease, confirmed by a blood or cer-
ebrospinal fluid culture, were reported (2012: 752, 
14/100,000). As before, the incidence was higher 
among men than among women (15 vs. 12/100,000). 
The regional variation between hospital districts was 
approximately double (10−24/100,000), which may 
be due to differences in how actively blood cultures 
are being taken. Children under the age of 5 account-
ed for 4.6% of the patients and over 65-year-olds for 
44.0%. The number of cases reported on the basis of 
antigen or nucleic acid detection totalled only 18. No 
serotype data is available for these cases and they are 
not included in the statistics.
In 2013, 721 cases of pneumococcal disease con-
firmed by culture were serotyped. These cases were 
divided into 40 serotypes or serogroups. Unlike in 
previous years, the most common serotype was 3 
(12.2%), followed by 14 (9.9%), 22F (9.9%), 19A 
(9.4%) and 4 (8.8%). These five most common sero-
types accounted for one half (50.3%) of all cases.
The 10-valent pneumococcal conjugate vaccine 
(PCV10) has been included in the basic vaccination 
programme for children since September 2010. The 
vaccines are administered at the age of 3, 5 and 12 
months. The effectiveness of the vaccination pro-
gramme is being monitored and the vaccination data 
of all children born on or after 1 June 2010, and who 
contract a severe case of pneumococcal disease, is in-
vestigated. In 2013, the number of severe cases of 
pneumococcal disease caused by the PCV10 vaccine 
serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) de-
creased further compared to the years before the vac-
cine was introduced (2008−2009). In children under 
2 years of age, six cases caused by PCV10 serotypes 
were diagnosed in 2013. All of these cases, except for 
one, involved children who had not yet been vacci-
nated because of their age or whose parents had not 
allowed them to be vaccinated. The number of cases 
caused by other than the PCV10 serotypes increased 
slightly in older age groups compared with the years 
before the vaccine was introduced.
Report 18/2014
National Institute for Health and Welfare
Infectious Diseases in Finland 2013
37
Figure 15. Serotypes of Streptococcus pneumoniae findings in blood and cerebrospinal fluid 2013 (no. of cas-
es). PVC10-serotypes, red columns. The column ”Other” includes serotypes that caused fewer than 10 cases.
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Antimicrobial sensitivity was determined for 668 
strains of invasive pneumococcus (Table 12). Strains 
with reduced susceptibility to penicillin (MIC > 0.06 
mg/L) accounted for 19% of the strains, and only 
one strain completely resistant to penicillin (MIC > 
2 mg/L) was detected. The percentage of macrolide-
resistant strains has also decreased further; 17% of in-
vasive pneumococcal strains were resistant to erythro-
mycin. Multiresistant strains (PEN IR-ERY R-TET 
R) accounted for 4% of the strains. No strains resist-
ant to levofloxacin (MIC > 2 mg/L) were found in 
2013. One strain was resistant to ceftriaxone (MIC > 
2 mg/L) (0.2%). It seems that the share of penicillin-
resistant strains and those with reduced susceptibility 
has begun to decline compared to 2012. The decline 
in macrolide resistance is also continuing.
haEmophilus (haEmophilus 
influEnzaE)
A total of 48 infections were caused by the Haemo-
philus influenzae bacterium and were diagnosed in 
blood or cerebrospinal fluid. This was on a par with 
the average rate in recent years, but was clearly less 
than in the peak year 2012 (81). More than one third 
of cases (38%) were diagnosed in patients aged 75 or 
older.
All cases were diagnosed through culture findings. 
The majority of these (38, 79%) were caused by un-
encapsulated strains of Haemophilus influenzae, as in 
earlier years. Serotype b caused an infection in a child 
under 2 years of age, serotype a in a one 6-month 
old baby and serotype f in five adults aged 38−78. 
Serotypes c, d and e did not occur at all. The serotype 
pcV10 vaccine serotypes non-vaccine serotypes un-
known
<2 2−4 5−64 65− total <2 2−4 5−64 65− total
2008 49 26 305 198 578 13 6 177 118 314 34
2009 47 26 301 166 540 12 4 149 117 282 33
2010 51 35 253 167 506 8 5 155 123 291 39
2011 34 16 232 150 432 11 11 172 145 339 8
2012 8 15 192 147 362 7 2 178 180 367 21
2013 6 3 173 110 292 13 11 197 208 429 3
Table 11. Streptococcus pneumoniae findings in blood and cerebrospinal fluid by age and vaccine serotype, 
2008–2013 (no. of cases).
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of three cases remained unknown because the strains 
were not received for typing by the National Institute 
for Health and Welfare.
In the case of serotype b, the patient was a 2-year-
old unvaccinated child diagnosed with severe epiglot-
titis. The vaccination programme designed to limit 
carriage of the bacteria in the throat has succeeded in 
limiting the circulation of serotype b in the popula-
tion, but cases can still occur in children with incom-
plete vaccination coverage. 
Children born in 1985 or later have received the Hib 
vaccine at the child care clinic. Since the beginning 
of 2005, under the revised vaccination programme 
the Hib vaccination is administered as a component 
in a combination vaccine at 3, 5 and 12 months. The 
efficiency of the vaccination is monitored, and vacci-
nation data are investigated for all children diagnosed 
with Hib.
mEningococcus (nEissEria 
mEningitidis)
In 2013, the number of meningococcus infections 
detected in blood or cerebrospinal fluid totalled 20 
(0.37/100,000), which is more than a third less than 
in the previous three years (Table 13). All cases were 
diagnosed through a culture finding, and all strains 
were serogrouped and genotyped. Ten (50%) were of 
serogroup B, 8 (40%) of serogroup Y, and 2 (10%) 
of serogroup C.
Unlike in previous years, no meningococcal infec-
tions were found in 5−29-year-olds. One half (10, 
50%) of the cases were diagnosed in 0−4-year-olds 
and one half (10, 50%) in patients over 30. The ma-
jority (80%) of cases caused by meningococcus of se-
rogroup B were diagnosed in young children, whereas 
all caused by group Y were in older age groups.
Genotyping showed that the group B strains were di-
vided into eight types. The most common type was 
B:P1.7-2,4:F1-5, which caused an infection in two 
children and one adult in various parts of the coun-
try. In 2012, the same aggressive strain infected four 
cases reported  
to the nIdr
studied  
strains
erythromycin 
(r) (%)
penicillin (I+r) 
(%)
multidrug  
resistance (%)
1998 561 84 3,6 0 0
1999 568 471 5,9 7,2 0
2000 601 439 8,0 3,7 1,4
2001 658 360 18,8 7,5 5,0
2002 599 594 16,3 8,0 3,7
2003 721 739 21,9 12,7 5,7
2004 748 748 20,5 9,6 3,7
2005 735 731 20,5 9,6 4,4
2006 741 760 27,9 16,4 5,4
2007 788 794 23,2 14,4 3,5
2008 924 930 24,5 17,7 3,4
2009 854 848 28,4 19,9 4,7
2010 827 819 28,6 23,4 1,7
2011 779 780 26,8 21,9 2,8
2012 751 754 22,2 27,7 5,0
2013 724 668 16,8 18,7 4,0
I – reduced susceptibility: R – resistant; Multidrug resistance – strains simultaneously resistant to penicillin (I+R), erythro-
mycin (R) and tetracycline (R)
Table 12. Antimicrobial resistance of Streptococcus pneumoniae findings in blood and cerebrospinal fluid, 
1998–2013 (no. of cases and %).
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Group a Group b Group c Group y Group W135 unknown total
2002 0 34 9 4 1 3 51
2003 0 36 6 4 1 2 49
2004 0 28 5 6 0 2 41
2005 0 29 5 4 2 4 44
2006 0 33 1 3 0 3 40
2007 0 38 5 1 0 1 45
2008 0 29 8 5 0 1 43
2009 0 19 8 2 0 0 29
2010 0 14 4 13 1 3 35
2011 0 19 6 7 1 1 34
2012 0 17 3 8 1 4 33
2013 0 10 2 8 0 0 20
Table 13. Meningococcal infections by serogroup, 2002–2013 (no. of cases).
people and in 2011, ten. Other strains of group B 
caused individual cases. Five types of group Y strains 
were identified. As in previous years, Y:P1.5-1,10-
1:F4-1 was most common, causing an infection in 
three adults in various parts of the country. The group 
C strains were divided into two types.
Early in 2013, a cluster caused by group B meningo-
coccus was diagnosed in southern Finland, causing 
a severe infection in three small children. However, 
genotyping showed that the cases were caused by dif-
ferent strains. In July 2013, infections caused by the 
same strain Y were detected in two adults in South-
west Finland, but no epidemiological connection was 
found between these two cases.
In sporadic cases of meningococcus, all persons in 
close contact with the patient except for health care 
personnel should be given prophylactic medication 
and also a vaccination, if infection from that strain 
can be prevented by vaccination. Finland has vac-
cines against the meningococcus serotype groups A, 
C, W135 and Y and the Defence Forces is admin-
istering a quadrivalent polysaccharide vaccination to 
all recruits. Otherwise, meningococcus vaccines are 
mainly used in connection with epidemics and travel. 
A new vaccine against group B meningococcus strains 
is coming on the market.
mmr dIseases (measles, 
mumps, rubella)
In 2013, two cases of measles were reported, on a par 
with recent years, but clearly less than in the peak 
year 2011 (27). Both patients were adults, one vac-
cinated as recommended and the other unvaccinated. 
One had travelled in South East Asia and the other 
had a contact with a person visiting Finland who was 
infected with measles.
One case of mumps in an adult was reported in 2013. 
Prior to falling ill, the patient had travelled in Eng-
land and was reportedly unvaccinated.
Two cases of rubella were diagnosed in Finland in 
2013, both in unvaccinated guest workers.
varicElla virus
The number of varicella findings reported to the 
NIDR was slightly lower than previously at 455 
(2012: 489). Of these findings, 227 were diagnosed 
by antigen detection, 98 by nucleic acid detection 
and 146 by serological diagnostics. There were 42 
(9%) reports based on a diagnosis from cerebrospinal 
fluid, involving the identification of a varicella nu-
cleic acid in 39 cases, a varicella antigen in three cases 
and varicella antibodies in nine cases.
The patients were aged between 0 and 92. Childhood 
varicella or chicken pox is a very common disease, 
with an estimated 57,000 cases in Finland every year. 
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Figure 16. Borrelia cases by hospital district, 2013 (no. of cases/100,000).
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It is mostly diagnosed clinically and does not even 
lead to a health care contact in the majority of the 
cases. By contrast, herpes zoster, or shingles, caus-
es far more use of health care services especially in 
the elderly, and this can be seen in the age distribu-
tion of virus findings. The incidence was 8/100,000 
on average, being highest in the over 65 age group: 
14/100,000 in the 65 to 69 age group, 13/100,000 
in the 70 to 74 age group and 15/100,000 in the over 
75 age group. Currently, varicella vaccination is rec-
ommended to everyone aged 13 or over who has not 
had chicken pox.
borrElia (lymE disEasE)
A total of 1,707 cases of borrelia were reported, 
roughly on a par with previous years (2012: 1,587, 
2011: 1,662 and 2010: 1,442 ). Of these reports, 27 
were based on nucleic acid detection and 1,670 on a 
serological test. The incidence in the whole country 
was 31/100,000 on average, but there was significant 
regional variation. The incidence was highest in the 
Åland Islands (1,621/100,000), accounting for more 
than a quarter of all diagnosed borrelia infections in 
Finland, 462 cases. As previously, the frequency of 
borrelia was highest in the autumn, from August to 
November. The majority of the patients (76 %) were 
aged over 45; 51 % of the patients were women.
tick-bornE EncEphalitis (tbE)
In 2013, 38 TBE antibody findings were reported to 
the National Infectious Diseases Register, similar to 
the figures for previous years. Positive TBE findings 
were reported between May and October, the largest 
number being reported in September. The patients 
who contracted TBE were aged between 1 and 76.
In order to identify the place of acquisition, the Na-
tional Institute for Health and Welfare interviewed 
patients who had been diagnosed with TBE in 2013 
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Place of acquisition
TBE virus found in ticks
Figure 17. Cases of TBE by location of acquisition, 2013, and TBE virus findings in ticks, 1996–2013. 
and/or studied their patient records. Nine patients 
contracted TBE on Åland, 25 in mainland Finland 
and four patients contracted TBE in areas with high 
incidence of TBE in Sweden, Switzerland, Estonia 
and Austria. All residents of Åland have been entitled 
to a TBE vaccination free of charge since 2006. How-
ever, two Åland residents were infected regardless of 
the vaccination.
Some of the cases in mainland Finland originated in 
previously known TBE risk areas: Parainen (6), Lap-
peenranta region (4), Simo (2) and the Kokkola/
Luoto archipelago (1). Hanhikivi in Pyhäjoki arose 
as a new probable area in terms of TBE infection (3) 
but individual infections were detected in other lo-
calities, including Outokumpu, Kuhmoinen, Espoo 
and Hanko, although no proof of a permanent risk of 
infection is as yet available. 
In addition to this year’s cases, previously identified 
places of infection include Närpiö, Maalahti and the 
Kotka and Sipoo archipelago, and the Kuopio region. 
As well as in Åland, the TBE virus was identified in 
ticks in the Turku archipelago and the Lappeenran-
ta region decades ago, and in collections performed 
in the following risk areas in recent years: Isosaari 
in Helsinki, the Kokkola archipelago, Maksniemi in 
Simo and the Kotka archipelago.
If a patient falls ill with meningitis or encephalitis 
between May and October even though he or she 
has not noticed a tick bite, TBE should be suspected, 
especially if this happens in known high-risk areas. 
Because new endemic TBE regions may continue to 
emerge, it is a good idea to consider the possibility 
of TBE infection even beyond currently known risk 
areas.
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puumala virus
In 2013, a total of 1,685 cases of Puumala virus were 
reported (31/100,000), which is about fifty percent 
more than in 2012 (841). The annual number of 
cases varies, depending on the virus reservoir, i.e. the 
size of the bank vole population. The variation usu-
ally follows a three-year cycle such that two abun-
dant years are followed by a quieter year. The previ-
ous peaks occurred in 2002, 2005 and 2008, with 
a slight increase also in 2011. Of the patients, 58% 
were men, and most patients were of working age. 
There were 77 (4.6%) under 20 years of age. The inci-
dence was highest in the Etelä-Savo Hospital District 
(151/100,000) and the Pohjois-Savo Hospital Dis-
trict (133/100,000).
pogosta disEasE (sindbis 
virus)
There were 99 cases confirmed with antibody testing, 
clearly less than in the previous year (2012: 189). The 
incidence was highest in the hospital districts of Cen-
tral Ostrobothnia and Vaasa (9.3 and 5.9 / 100,000, 
respectively). Of the patients, 82 (83%) were of work-
ing age, aged 20 to 64, and 60 (61%) were women. 
The majority of the cases, 89 (90 %), were diagnosed 
between July and September.
The Sindbis virus is principally transmitted by mos-
quito species prevalent in late summer. Temperatures 
in early summer and rainfall and snowfall in the pre-
vious winter significantly affect incidence. Waterway 
regulation, other local ecological and socioeconomic 
factors together with cyclical variation in available 
animal reservoirs (forest game birds) may also play a 
role in the incidence of the disease in Finland. Cases 
Figure 18. Cases of Puumala virus by hospital district, 2013 (no. of cases per 100,000 population).
Puumala virus
cases/100,000 population
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of Pogosta disease tend to cluster in the period from 
late July to September.
A Sindbis infection that presents with symptoms 
is more common in Finland than elsewhere in the 
world. The virus has an incubation period of one 
week, after which the infection presents with a fe-
ver commonly accompanied by rash and muscle and 
joint symptoms. The joint pain may persist for years 
in some patients, and is not always easy to associate 
with Pogosta disease. Genetic susceptibility is prob-
ably a factor both in contracting the infection and in 
the presentation of symptoms.
Pogosta disease has followed a regular seven-year cy-
cle since 1974 except for 2009. The epidemic peaked 
in 1981, 1995 and 2002; in 2009, however, only 106 
cases were found (2/100,000).
tularEmia (francisElla 
tularEnsis)
In 2013, a record low number of tularemia cases, 
only 15, were reported (incidence 0.28/100,000). Of 
these, four were detected in the South Ostrobothnia 
and four in Central Finland Hospital District, oth-
ers being distributed as individual cases in different 
hospital districts. Twelve cases (86%) were diagnosed 
in men, the majority, 11 cases, being diagnosed in 
July−September.
The annual incidence of tularemia varies considerably 
(between 0.3 and 18/100,000). Epidemics, which oc-
cur in a cycle of a few years, tend to be local. Because 
tularemia bacteria are mainly transmitted by insect 
bites, the incidence of the disease peaks in late sum-
mer. So far, it is unknown what local ecological cir-
cumstances might explain the differences in incidence 
between hospital districts.
rabiEs
Doctors are required to report cases where risk assess-
ment has led to the start of rabies vaccination treat-
ment after exposure. In 2013, 88 reports were made, 
clearly more than in 2012 (56). A further six suspect-
ed cases were reported in the Helsinki and Uusimaa 
Hospital District in which the exposure had occurred 
in 2012. These suspected cases are not included in the 
following figures.
There were 50 patients who had been exposed abroad: 
19 in Thailand and ten in Russia and more than one 
case of exposure in Turkey, Estonia, Greece and India, 
respectively. More than a half of the cases of exposure 
were related to dog bites. Exposure in Finland was re-
ported in 38 cases, of which 18 (47%) were associat-
ed with a dog bite. In all cases of exposure in Finland 
involving a dog, the dog had been imported to Fin-
land from a country where rabies occurs. Seven cases 
of exposure involving a bat were reported, and three 
involving  accidental exposure to rabies bait vaccine.
malarIa, denGue feVer 
and othEr travEl-rElatEd 
infEctions
malaria
Malaria was diagnosed in 40 patients in Finland in 
2013. There were 27 cases of Plasmodium falciparum, 
one case of P. falciparum-P. ovale double infection, and 
six of P. vivax and six P. ovale. Most infections were 
continent country cases
Asia India 2
Pakistan 1
Total 3
Africa Southern Sudan 2
Ethiopia 1
Gambia 4
Ghana 3
Cameroon 4
Kenya 4
Mali 1
Mauritania 1
Nigeria 8
Ivory Coast 1
Zambia 1
Sierra Leone 3
Tanzania 1
Chad 1
Uganda 1
Total 36
Oceania Papua New Guinea 1
Total 1
total 40
Table 14. Malaria cases in Finland in 2013 by country 
of acquisition.
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contracted in Africa (36 cases, or 90%), 26 in western 
Africa. Three infections were acquired on the Indian 
subcontinent, and one in Oceania. Of the patients, 
eight (20%) were native Finns who had been travel-
ling in a areas with malaria for less than six months, 
and four were Finns resident in a malarious area; 21 
(53%) were immigrants from a malarious area who 
had been visiting their home country, six were im-
migrants who had fallen ill immediately after arriv-
ing in Finland, and one was a visitor to Finland. The 
countries in which patients contracted malaria and 
the risk groups remained approximately the same as 
in previous years.
dengue fever
Dengue fever cases have been on the increase in re-
cent years, with 35 to 50 cases per year. Some 90 cases 
were reported in 2012. The corresponding figure for 
2013 was 80, of which the majority (75/80) occurred 
in 15−59-year-olds. In addition, five cases were diag-
nosed in 60−74-year-olds, but none in the under 15 
or over 75 age groups. The majority were diagnosed 
in January, February and March. Comprehensive data 
on the countries of acquisition is not available.
other travel-related infections
A significant percentage of the following infections 
are travel-related: legionella, salmonella, campylo-
bacter, shigella, EHEC, hepatitis A, hepatitis B, gon-
orrhoea, syphilis, HIV and AIDS, carbapenem-resist-
ant gram-negative bacilli and MMR diseases; data on 
the country of acquisition and means of transmission 
is discussed separately for each of these diseases in its 
respective section.
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blood and cErEbrospinal 
fluid findings in childrEn
blood culture findings in children
The number of blood culture positive cases reported 
in children under 15 in 2013 was 386, slightly less 
than in recent years (average between 2000 and 2012 
was 600, variation 426−686).
Approximately one half of the findings (192 out of 
386) were in babies under 12 months old. Among 
infants, Staphylococcus epidermidis and other coag-
ulase-negative staphylococci caused 37% of blood 
culture positive infections (table 15). Though these 
bacteria belong to the normal skin flora, they typi-
cally cause late-onset sepsis in newborn babies in in-
tensive care. The second most common cause (16% 
of the findings) was Streptococcus agalactiae (Group B 
streptococcus, GBS). It is typically contracted from 
the mother’s birth canal during labour and causes an 
infection (early-onset sepsis) in the newborn baby 
during its first days of life. Other common causes of 
infection were Escherichia coli (19% of the findings), 
Staphylococcus aureus (9%) and Streptococcus pneumo-
niae (4%).
In the age group 1 to 14 years, S. aureus was the most 
common cause of blood culture positive infections in 
2013 (25%) (Table 16). As in 2012, the incidence of 
the previous leading cause, S. pneumoniae, was less 
than half of what it had been in previous years (18%). 
A pneumococcus vaccination for children was add-
ed to the national vaccination programme in 2010. 
Other common findings in this age group were coag-
ulase-negative staphylococci (17%), the Streptococcus 
viridans group (5%) and E. coli (5%).
cerebrospinal fluid findings in children
The number of bacterial and fungal findings related to 
children’s central nervous system infections remained 
at the same level as in the preceding years, as did the 
distribution of pathogens. The total number of cases 
reported in 2013 was 21 (the annual average from 
2000 to 2012 was 35, variation 18−56), of which 
10 were diagnosed in infants under 12 months old. 
The most common findings in the under 12 month 
age group were meningococcus, S. epidermidis and S. 
pneumoniae (Table 17); in the 1 to 14 year age group, 
S.pneumoniae and meningococcus were most com-
mon (Table 18).
Gbs in newborns
Between 1995 and 2012, an average of 32 cases per 
year of early-onset GBS in newborns (diagnosed from 
blood and/or CSF in children under the age of 7 
days) were reported; the variation was 20 to 57 cases 
per year, and the incidence was 0.3 to 1.0 per 1,000 
live births. There were 20 cases in 2013 (0.3 cases 
per 1,000 live births). An average of 15 annual cases 
of late GBS disease cases detected at the age of more 
than 7 days have occurred during the fifteen-year sur-
veillance period (range 6−24; incidence 0.1–0.4 cases 
per 1,000 live births). There were 11 cases in 2013 
(0.2 cases per 1,000 live births).
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Staphylococcus epidermidis 76 61 110 98 100 92 87 64 71 76 50 47
Escherichia coli 40 39 37 41 44 42 38 38 45 48 25 36
Streptococcus agalactiae 46 37 45 73 55 51 49 51 54 42 36 31
Staphylococcus, other 
coagulase-negative
35 20 36 31 41 39 33 43 32 33 26 24
Staphylococcus aureus 24 21 32 32 37 25 23 22 24 21 31 18
Streptococcus pneumoniae 17 25 28 26 27 21 26 25 20 11 8 8
Streptococcus viridans 
group
8 13 15 12 10 9 8 9 18 11 3 5
Klebsiella species 7 8 9 9 8 6 8 9 3 7 6 4
Neisseria meningitidis 2 2 5 3 2 3 3 5 4 1 2 4
Enterobacter species 6 6 5 3 13 8 6 3 3 10 5 3
Acinetobacter species 4 3 1 1 3 2 1 1 3 2 1 2
Bacillus 0 1 2 2 1 4 4 2 1 1 1 1
Haemophilus influenzae 0 4 1 2 1 1 2 2 1 0 4 1
Listeria monocytogenes 0 0 0 0 2 1 0 1 2 0 1 1
Salmonella, other than Typhi 1 0 0 0 0 0 0 1 0 1 0 1
Serratia species 5 2 4 0 2 3 4 1 2 4 0 1
Streptococcus pyogenes 1 1 3 0 0 3 2 4 2 0 6 1
Bacteroides fragilis group 0 0 0 0 0 1 1 0 1 0 0 0
Citrobacter species 1 1 0 1 1 0 0 1 1 0 1 0
Clostridium perfringens 1 0 0 1 0 0 0 0 0 0 0 0
Clostridium, other or 
unidentified
0 1 1 0 2 0 1 1 1 0 2 0
Enterococcus faecalis 11 11 9 15 22 8 5 10 20 12 11 0
Enterococcus faecium 2 2 3 2 3 0 1 2 2 1 0 0
Enterococcus, other or 
unidentified
0 0 1 0 0 0 0 2 0 0 1 0
Haemophilus, other than 
influenzae
0 1 0 1 1 0 1 0 0 1 0 0
Morganella morganii 0 0 0 0 0 0 0 0 0 0 0 0
Table 15. Blood culture findings in infants (under 12 months), 2002–2013 (no. of cases).
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Peptostreptococcus and 
Peptococcus 0 0 0 0 0 0 0 0 1 0 0 0
Prevotella species 0 0 0 0 0 0 1 0 0 0 0 0
Propionibacterium species 1 0 0 0 0 1 0 0 0 1 0 0
Proteus mirabilis 0 0 1 0 1 1 0 0 0 0 0 0
Proteus vulgaris 0 0 0 0 0 0 0 0 0 0 0 0
Pseudomonas aeruginosa 1 1 4 0 0 0 2 0 2 1 0 0
Stenotrophomonas 
maltophilia 1 1 0 1 0 2 0 2 2 0 0 0
Streptococcus bovis group 1 1 1 1 0 0 0 2 0 0 0 0
Streptococcus milleri group 1 0 0 0 1 0 0 0 0 0 0 0
Streptococcus, other beta-
haemolytic
1 1 2 0 1 0 0 3 2 0 1 0
Veillonella species 0 0 0 0 1 0 0 0 0 0 0 0
Other bacteria 12 9 8 4 5 10 7 5 4 10 6 3
bacteria, total 305 272 363 359 384 333 313 309 321 294 227 191
Candida albicans 10 2 3 4 4 2 3 1 2 1 1 1
Other candida species 8 2 0 1 0 1 1 0 0 1 2 0
Other fungi 0 0 0 0 0 1 0 0 0 0 0 0
fungi, total 18 4 3 5 4 4 4 1 2 2 3 1
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Staphylococcus aureus 58 47 58 41 37 43 40 36 43 42 47 48
Streptococcus pneumoniae 92 94 88 101 99 115 87 92 95 74 35 35
Staphylococcus epidermidis 40 30 25 41 40 33 22 31 37 29 17 25
Streptococcus viridans 
group
13 13 18 24 24 23 21 25 36 20 14 16
Escherichia coli 13 13 15 10 16 12 14 12 15 11 14 9
Staphylococcus, other 
coagulase-negative
14 16 9 13 8 18 13 16 21 13 11 8
Streptococcus pyogenes 10 12 4 0 9 13 11 11 6 16 9 8
Bacillus 5 6 2 7 6 0 6 3 3 2 5 5
Pseudomonas aeruginosa 4 6 3 6 3 2 1 3 7 4 3 4
Salmonella, other than Typhi 1 1 1 1 2 5 2 0 6 2 3 4
Acinetobacter species 8 2 1 4 1 2 2 4 1 0 1 3
Haemophilus influenzae 1 6 0 1 1 2 3 3 2 5 0 3
Klebsiella species 6 4 5 10 3 6 5 2 4 2 6 3
Neisseria meningitidis 8 6 2 7 5 3 4 0 6 2 2 3
Fusobacterium species 3 0 1 2 3 5 5 1 1 1 1 1
Haemophilus, other than 
influenzae
0 0 0 0 0 0 0 0 0 0 1 1
Listeria monocytogenes 0 1 0 0 0 0 0 0 0 0 0 1
Propionibacterium species 0 1 0 0 0 0 0 0 0 0 2 1
Salmonella Typhi 1 1 1 2 0 2 0 0 0 2 0 1
Serratia species 1 0 0 1 2 1 0 0 1 0 0 1
Stenotrophomonas 
maltophilia 0 1 3 0 1 3 4 2 2 0 1 1
Bacteroides fragilis group 1 0 2 3 0 0 0 1 0 2 0 0
Bacteroides, other than 
fragilis group
0 0 0 0 0 0 0 0 0 0 0 0
Campylobacter species 0 0 0 0 0 0 0 0 0 0 0 0
Citrobacter species 1 0 0 1 0 2 2 1 1 0 0 0
Clostridium perfringens 0 1 0 0 1 2 0 1 1 0 0 0
Table 16. Blood culture findings in children (aged 1 to 14), 2002–2013 (no. of cases).
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Clostridium, other or 
unidentified
2 1 0 3 2 4 1 1 2 1 2 0
Enterobacter species 1 6 3 3 1 2 4 3 2 3 1 0
Enterococcus faecalis 4 2 2 4 2 6 6 4 6 3 5 0
Enterococcus faecium 4 1 2 2 3 4 2 7 7 0 1 0
Enterococcus, other or 
unidentified
0 2 2 0 2 2 3 0 1 0 0 0
Mycobacterium, other or 
unidentified 
0 0 0 0 0 0 0 0 0 1 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 0 0 0 0 0 0 2 1 0
Prevotella species 0 0 1 0 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 1 0 0 1 0 0 0 0 0 0
Pseudomonas, other than  
aeruginosa
1 1 0 1 0 1 0 3 0 0 0 0
Streptococcus agalactiae 0 2 1 0 0 2 1 0 0 0 0 0
Streptococcus bovis group 0 0 0 0 1 0 0 0 0 0 0 0
Streptococcus milleri group 1 0 0 3 2 0 2 2 2 1 1 0
Streptococcus, other beta-
haemolytic
0 3 2 2 4 1 0 2 2 1 1 0
Veillonella species 0 0 0 0 1 0 0 0 1 0 0 0
Yersinia pseudotuberculosis 0 1 0 0 0 0 0 0 0 0 0 0
Other bacteria 16 11 18 22 14 15 10 10 24 10 11 10
bacteria, total 309 291 270 315 293 330 271 276 335 249 195 191
Candida albicans 2 1 0 1 1 0 2 0 2 0 1 2
Other candida species 0 0 1 0 2 3 1 0 0 2 0 1
Other fungi 1 2 0 0 2 1 0 0 0 1 0 0
fungi, total 3 3 1 1 5 4 3 0 2 3 1 3
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Neisseria meningitidis 1 2 4 0 1 2 1 2 1 0 3 3
Staphylococcus epidermidis 3 3 3 3 3 2 1 2 2 2 1 3
Streptococcus pneumoniae 3 6 8 3 1 4 3 2 3 2 1 2
Staphylococcus aureus 0 3 2 1 0 1 2 2 1 0 3 1
Acinetobacter species 1 0 0 0 1 0 0 0 0 0 0 0
Bacillus 0 0 0 0 1 0 0 0 0 0 0 0
Bacteroides, other than 
fragilis group
0 0 0 0 0 1 0 0 0 0 0 0
Citrobacter species 0 0 0 0 0 1 0 0 1 0 0 0
Enterobacter species 0 0 1 0 0 0 0 0 0 0 0 0
Enterococcus faecalis 0 1 1 0 2 1 0 0 0 0 0 0
Enterococcus faecium 0 0 0 0 1 0 0 0 0 0 0 0
Escherichia coli 1 1 2 0 2 1 1 1 2 1 0 0
Haemophilus influenza 0 1 0 1 0 0 0 1 0 0 0 0
Klebsiella species 0 0 0 0 0 0 0 1 0 0 1 0
Mycobacterium, other than 
avium
0 0 0 0 0 0 0 0 1 0 0 0
Propionibacterium species 0 1 1 0 0 0 0 0 0 0 0 0
Serratia species 0 0 1 0 0 0 0 0 0 0 0 0
Staphylococcus, other 
coagulase-negative
4 1 2 1 0 0 4 1 0 0 2 0
Streptococcus agalactiae 5 1 10 7 7 6 3 6 8 2 3 0
Streptococcus pyogenes 0 0 0 0 0 0 0 1 0 0 0 0
Streptococcus viridans 
group
0 1 0 0 0 0 0 2 0 1 0 0
Other bacteria 2 1 1 0 0 0 0 1 0 0 0 1
bacteria, total 20 22 36 16 19 19 15 22 19 8 14 10
Candida albicans 0 0 0 0 0 0 0 1 0 0 0 0
fungi, total 0 0 0 0 0 0 0 1 0 0 0 0
Table 17. Cerebrospinal fluid culture findings in infants (under 12 months), 2002–2013 (no. of cases).
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Table 18. Cerebrospinal fluid culture findings in children (aged 1 to 14), 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Streptococcus pneumoniae 2 10 2 1 5 5 2 4 2 3 0 4
Neisseria meningitidis 7 4 4 5 7 5 3 2 3 4 2 3
Staphylococcus aureus 1 2 2 0 0 2 3 3 2 2 2 1
Staphylococcus, other 
coagulase-negative
3 2 2 2 0 0 0 1 0 0 0 1
Acinetobacter species 1 0 1 1 0 0 0 0 0 0 0 0
Bacteroides fragilis group 0 0 0 0 1 0 0 0 0 0 0 0
Citrobacter species 1 0 0 0 0 0 0 0 0 0 0 0
Corynebacterium species 0 0 0 0 0 0 2 0 1 0 0 0
Enterobacter species 0 0 1 0 0 0 0 1 0 0 1 0
Enterococcus faecalis 0 0 1 1 0 0 0 0 1 0 0 0
Enterococcus faecium 1 0 1 0 0 0 0 0 0 0 0 0
Escherichia coli 0 0 0 0 1 0 0 0 0 0 1 0
Haemophilus influenzae 0 4 0 0 0 0 0 0 0 1 0 0
Mycobacterium, other than 
avium
0 1 0 0 0 0 0 0 0 0 0 0
Peptostreptococcus and 
Peptococcus 0 0 0 0 1 0 0 0 0 0 0 0
Propionibacterium species 0 0 0 1 0 0 0 0 0 1 0 0
Staphylococcus epidermidis 7 1 4 2 0 1 5 2 1 2 1 0
Stenotrophomonas 
maltophilia 0 1 0 0 0 0 0 0 0 0 0 0
Streptococcus agalactiae 0 0 0 0 0 0 0 0 0 0 0 0
Streptococcus pyogenes 1 0 0 0 0 0 0 0 0 0 1 0
Streptococcus viridans 
group
0 1 1 0 2 0 0 0 0 0 0 0
Streptococcus, other beta-
haemolytic
1 0 0 0 0 0 0 1 0 0 0 0
Other bacteria 5 0 0 5 1 0 6 3 1 4 2 2
bacteria, total 30 26 19 18 18 13 21 17 11 17 10 11
Candida albicans 0 0 1 0 0 0 0 0 0 0 1 0
fungi, total 0 0 1 0 0 0 0 0 0 0 1 0
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blood and cErEbrospinal 
fluid findings in adults
blood culture findings in adults
The total number of blood culture findings in adults 
in 2013 was 11,658 (2012: 11,096). The number 
of blood culture findings in the over 65 age group 
continued to grow, as previously, being 7,614 (2012: 
7153). Gram-positive bacteria were more common 
in the working-age population (aged 15 to 64) and 
gram-negative bacteria among those aged 65 or more. 
Anaerobic bacteria constituted 5% and fungi 2% of 
all blood culture positive findings among adults.
In the working-age population, the most common 
bacterial finding was Escherichia coli, constituting al-
most a quarter of all cases (Table 19). The next most 
common findings were Staphylococcus aureus (16%), 
Streptococcus pneumoniae (9%), coagulase-negative 
staphylococci (9 %), and Klebsiella species (5%).
E. coli was also the most common blood culture 
finding among patients aged 65 years or more, ac-
counting for a third of all findings (Table 20). The 
next most common findings were S. aureus (12%), 
coagulase-negative staphylococci (8%) and Klebsiella 
species (7 %).
cerebrospinal fluid findings in adults
The total number of cerebrospinal fluid findings in 
adults in 2013 was 112 (2000–2012 average 141, 
variation 36−191). Patients over the age of 65 ac-
counted for 39% of the cases (44 out of 112).
Coagulase-negative staphylococcus was reported in 
34 per cent of cases involving working-age patients 
(Table 22). The most common actual pathogens were 
pneumococcus (19%) and S. aureus (16%). In pa-
tients aged 65 years or older, coagulase-negative sta-
phylococcus accounted for 27% of the findings (Ta-
ble 23). The most commonly reported actual patho-
gens were S. aureus (23%), pneumococcus (14%) and 
Listeria monocytogenes (9%).
Group a streptococcus
In 2013, the number of invasive infections of Group 
A streptococcus (Streptococcus pyogenes) decreased 
slightly in comparison with the previous year (2013: 
191 and 2012: 216). The prevalent emm types of 
Group A streptococcus were the same as in previous 
years: emm1, emm28 and emm89. The appearance 
of the macrolide-resistant type emm33 in 2012 (5; 
2%) is noteworthy, as is the increase during 2013 (13; 
7%). In addition to the aforementioned, the share of 
emm12 has steadily remained elevated (5%). The 
previously common type emm84 was not detected at 
all in 2013. Although new emm types continuously 
emerge, the four most common emm types account-
ed for 72% of all cases in 2013 (Table 21).
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Table 19. Blood culture findings in patients aged 15 to 64, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Escherichia coli 580 645 707 780 797 837 871 885 930 935 942 951
Staphylococcus aureus 462 448 488 459 565 549 529 540 585 645 622 653
Streptococcus pneumoniae 333 406 386 377 348 353 480 441 413 393 362 356
Klebsiella species 134 121 159 184 145 159 198 187 207 164 216 220
Staphylococcus epidermidis 305 286 294 286 281 265 279 313 264 223 181 210
Streptococcus, other beta-
haemolytic 78 80 101 96 127 117 113 113 131 139 119 156
Staphylococcus, other 
coagulase-negative 138 114 126 113 120 141 151 137 139 143 104 153
Streptococcus pyogenes 93 78 100 76 105 134 157 118 113 102 126 110
Streptococcus viridans 
group 105 126 141 141 130 118 140 144 150 139 88 106
Bacteroides fragilis group 61 59 67 83 85 82 109 68 110 109 103 102
Streptococcus milleri group 48 48 48 54 62 64 72 57 68 86 78 98
Streptococcus agalactiae 78 68 64 99 76 83 96 95 110 75 89 96
Pseudomonas aeruginosa 73 85 58 88 62 72 74 78 91 92 79 91
Enterobacter species 53 60 62 49 77 70 69 82 99 86 96 90
Bacillus 18 22 15 18 22 24 25 21 32 34 27 42
Fusobacterium species 15 21 32 31 19 31 31 27 37 31 48 41
Salmonella, other than 
Typhi 12 22 35 29 50 58 48 26 42 33 35 37
Serratia species 12 14 10 16 18 19 24 27 20 32 25 32
Citrobacter species 14 10 21 15 28 19 23 29 31 28 25 23
Peptostreptococcus and 
Peptococcus 22 23 15 21 18 11 12 27 15 30 18 22
Proteus mirabilis 15 11 15 12 18 14 14 18 26 17 24 22
Haemophilus influenzae 9 33 11 13 9 26 18 19 18 22 25 20
Morganella morganii 3 4 4 3 8 7 14 8 6 8 7 18
Capnocytophaga 
canimorsus 6 6 6 8 8 8 8 11 11 17 13 14
Clostridium, other or 
unidentified 28 14 17 22 20 15 19 20 22 19 16 14
Stenotrophomonas 
maltophilia 14 6 12 12 7 5 15 12 12 9 7 14
Acinetobacter species 13 10 16 16 10 21 13 18 14 21 14 11
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Listeria monocytogenes 9 12 7 10 10 9 8 9 15 7 17 11
Prevotella species 4 11 11 15 11 8 13 13 15 16 16 10
Propionibacterium species 8 11 6 9 7 5 3 9 6 9 7 9
Pseudomonas, other than 
aeruginosa 3 4 5 4 0 4 9 7 7 7 8 9
Veillonella species 2 3 1 6 3 5 3 7 5 13 6 9
Campylobacter species 7 10 13 5 3 8 7 11 10 4 6 8
Clostridium perfringens 6 9 6 16 11 12 10 16 16 8 11 8
Bacteroides, other than 
fragilis group 5 0 5 2 4 3 5 10 1 7 3 7
Mycobacterium avium 0 1 0 2 2 2 1 2 2 2 3 5
Neisseria meningitidis 20 18 18 16 20 21 9 13 14 17 12 5
Salmonella Typhi 1 3 4 3 3 4 1 3 9 3 1 5
Haemophilus, other than 
influenzae 4 1 5 6 3 3 3 0 2 3 9 4
Streptococcus bovis species 2 2 3 8 5 7 1 6 7 6 6 4
Mycobacterium, other or 
unidentified 1 4 0 1 2 3 1 0 0 2 1 3
Proteus vulgaris 0 3 4 3 7 3 2 3 2 2 3 2
Hafnia alvei 1 5 4 3 0 1 3 6 2 2 2 1
Yersinia pseudotuberculosis 2 1 1 0 0 0 1 0 0 0 1 1
Enterococcus faecalis 99 84 80 100 83 105 83 107 86 97 78 0
Enterococcus faecium 53 51 45 66 69 81 91 89 91 108 64 0
Enterococcus, other or 
unidentified 14 10 10 11 6 4 7 13 13 12 16 0
Yersinia enterocolitica 0 0 0 1 0 0 0 1 1 0 0 0
Other bacteria 92 84 89 93 97 84 103 99 90 93 104 131
bacteria, total 3055 3147 3327 3481 3561 3674 3966 3945 4090 4050 3863 3934
Candida albicans 29 43 45 42 54 55 55 55 57 74 56 64
Other candida species 23 35 24 22 22 25 42 28 37 30 31 42
Other fungi 2 1 2 1 2 2 4 5 2 5 2 4
fungi, total 54 79 71 65 78 82 101 88 96 109 89 110
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Table 20. Blood culture findings in patients aged 65 or over, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Escherichia coli 1213 1314 1466 1624 1706 1760 1890 2056 2233 2481 2474 2881
Staphylococcus aureus 452 467 486 484 602 570 675 692 731 783 800 883
Klebsiella species 230 253 341 339 326 338 420 462 468 473 537 559
Staphylococcus epider-
midis 228 231 254 284 265 275 299 270 325 316 299 344
Streptococcus, other beta-
haemolytic 100 123 135 140 174 171 177 222 258 267 294 322
Streptococcus 
pneumoniae 200 241 239 229 270 294 326 294 303 296 343 319
Staphylococcus, other 
coagulase-negative 134 112 114 116 129 139 165 155 143 156 170 251
Pseudomonas aeruginosa 148 148 139 151 154 188 191 184 218 196 249 230
Bacteroides fragilis group 96 118 120 135 119 135 146 164 178 203 183 203
Enterobacter species 87 97 92 115 95 105 131 128 156 157 172 189
Streptococcus viridans 
group 83 103 103 106 110 115 140 135 132 138 89 141
Streptococcus agalactiae 49 62 76 84 81 77 94 104 126 113 117 129
Proteus mirabilis 57 62 80 57 68 93 99 102 106 98 130 119
Citrobacter species 40 44 43 42 42 35 65 59 76 59 95 100
Streptococcus milleri 
group 28 43 45 50 67 54 53 62 59 58 65 92
Serratia species 15 28 18 33 27 33 50 37 59 56 65 81
Streptococcus pyogenes 46 28 33 34 48 58 50 63 50 50 75 72
Listeria monocytogenes 11 19 18 20 26 26 26 20 44 31 36 45
Clostridium perfringens 26 27 32 29 36 39 34 49 40 51 56 35
Peptostreptococcus and 
Peptococcus 14 20 13 17 22 25 14 29 36 26 24 32
Morganella morganii 13 10 14 21 14 26 11 18 29 30 16 30
Streptococcus bovis group 7 9 20 12 17 17 15 25 12 12 17 26
Acinetobacter species 17 8 13 10 18 11 12 16 16 17 19 21
Haemophilus influenzae 15 32 13 28 21 25 21 22 19 37 51 20
Fusobacterium species 16 7 13 10 9 15 10 8 17 14 19 18
Bacillus 11 10 10 10 17 9 11 12 7 14 7 17
Clostridium, other or 
unidentified 23 18 25 21 22 31 18 27 35 24 26 17
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Proteus vulgaris 7 8 7 9 9 9 4 4 8 8 12 14
Bacteroides, other than 
fragilis group
3 5 8 4 3 5 8 13 8 8 16 12
Capnocytophaga 
canimorsus 1 1 1 1 4 2 3 2 2 6 7 12
Pseudomonas, other than 
aeruginosa 6 6 3 7 9 11 10 11 10 8 11 12
Stenotrophomonas 
maltophilia 3 6 10 6 10 8 3 6 7 4 8 12
Prevotella species 11 4 11 10 10 8 11 15 13 14 7 11
Veillonella species 0 1 1 7 2 6 9 5 4 6 5 10
Salmonella, other than 
Typhi 7 5 6 14 11 8 19 6 8 7 13 9
Propionibacterium species 15 4 8 13 9 4 5 9 10 13 6 7
Haemophilus, other than 
influenzae 2 1 3 2 2 1 1 1 1 0 3 6
Hafnia alvei 1 1 4 4 3 6 8 7 7 1 8 6
Enterococcus, other or 
unidentified 18 19 16 17 19 15 24 20 24 33 26 5
Campylobacter species 3 1 5 3 5 3 5 6 3 1 4 4
Neisseria meningitidis 4 4 3 2 5 2 6 6 6 6 5 4
Mycobacterium, other or 
unidentified 0 2 3 0 5 1 3 0 5 1 1 1
Enterococcus faecalis 149 146 192 183 202 220 217 222 229 275 216 0
Enterococcus faecium 48 76 97 74 108 132 126 175 180 198 135 0
Mycobacterium avium 1 0 0 1 0 0 1 0 0 0 0 0
Salmonella Typhi 0 1 0 1 0 0 0 0 0 0 0 0
Yersinia enterocolitica 1 3 1 1 1 1 0 1 1 0 3 0
Yersinia 
pseudotuberculosis 1 1 2 2 1 1 0 3 1 0 1 0
Other bacteria 68 87 96 96 96 82 124 123 121 143 140 176
bacteria, total 3708 4016 4432 4658 4999 5189 5730 6050 6524 6888 7055 7477
Candida albicans 39 63 51 39 54 56 66 49 93 65 70 77
Other candida species 31 46 27 25 22 27 25 42 33 44 39 59
Other fungi 0 3 0 3 0 0 2 0 0 4 0 1
fungi, total 70 112 78 67 76 83 93 91 126 113 109 137
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cases 
notified to 
nidr
stains 
exam-
ined
emm1 emm28 emm84 emm89 emm33 other nt
2006 163 25 (15 %) 33 (20 %) 24 (15 %) 11 (7 %) 0 (0 %) 59 (36 %) 11 (7 %)
2007 205 58 (28 %) 26 (13 %) 32 (16 %) 12 (6 %) 0 (0 %) 72 (35 %) 5 (2 %)
2008 225 52 (23 %) 47 (21 %) 9 (4 %) 10 (4 %) 0 (0 %) 102 (45 %) 5 (2 %)
2009 191 25 (13 %) 56 (29 %) 4 (2 %) 29 (15 %) 0 (0 %) 74 (39 %) 3 (2 %)
2010 167 22 (13 %) 37 (22 %) 4 (2 %) 26 (16 %) 0 (0 %) 77 (46 %) 1 (<1 %)
2011 163 25 (15 %) 37 (23 %) 4 (2 %) 30 (18 %) 0 (0 %) 66 (40 %) 1 (<1 %)
2012 210 23 (11 %) 66 (31 %) 1 (<1 %) 58 (28 %) 5 (2 %) 52 (25 %) 5 (2 %)
2013 176 13 (7 %) 58 (33 %) 0 (0 %) 43 (24 %) 13 (7 %) 49 (28 %) 0 (0 %)
Table 21. Group A Streptococcus blood findings by emm-type, 2006–2013 (no. of cases and %).
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Table 22. Cerebrospinal fluid culture findings in patients aged 15 to 64, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Streptococcus 
pneumoniae 19 26 21 16 17 14 26 19 14 12 18 13
Staphylococcus 
epidermidis 27 21 24 34 32 17 27 18 11 10 21 12
Staphylococcus aureus 6 10 17 10 9 16 13 13 12 20 15 11
Staphylococcus, other 
coagulase-negative 12 6 16 14 12 7 14 10 8 6 7 11
Propionibacterium species 6 6 11 5 5 5 4 4 7 4 5 7
Enterobacter species 1 0 3 5 2 2 9 3 1 2 4 2
Haemophilus influenzae 2 0 1 0 0 0 3 1 0 2 1 2
Listeria monocytogenes 0 2 1 0 2 1 1 2 1 1 1 2
Campylobacter species 0 0 0 1 0 0 0 0 0 0 0 1
Corynebacterium species 0 1 1 2 1 1 0 1 0 0 1 1
Escherichia coli 3 0 0 7 4 3 3 4 1 1 2 1
Klebsiella species 0 0 0 0 0 0 4 2 1 2 0 1
Neisseria meningitidis 19 15 11 15 20 16 4 9 6 7 6 1
Pseudomonas aeruginosa 5 4 2 4 6 3 4 5 3 1 4 1
Streptococcus agalactiae 1 0 2 0 1 5 2 0 2 0 1 1
Acinetobacter species 2 1 1 3 3 5 2 3 0 2 2 0
Bacillus 5 0 0 3 6 4 3 0 0 0 2 0
Capnocytophaga 
canimorsus 0 0 0 0 0 0 0 1 0 0 1 0
Citrobacter  species 0 1 1 2 0 1 0 0 1 0 1 0
Enterococcus faecalis 2 3 5 3 4 5 4 3 4 3 3 0
Enterococcus faecium 1 0 2 1 0 1 0 1 0 2 2 0
Enterococcus, other or 
unidentified 1 0 0 0 1 1 1 0 0 1 0 0
Haemophilus, other than 
influenzae 0 0 0 0 0 1 0 0 0 2 0 0
Morganella morganii 1 0 0 0 0 0 0 0 0 0 0 0
Mycobacterium, other 
than avium 2 1 0 0 0 1 2 0 0 0 2 0
Peptostreptococcus and 
Peptococcus 0 2 0 0 0 0 0 1 0 0 0 0
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Prevotella species 1 0 0 0 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 0 0 0 0 0 0 0 1 0 0
Pseudomonas, other than 
aeruginosa 0 1 0 0 1 1 1 1 0 1 0 0
Salmonella, other than 
Typhi 0 1 0 0 0 0 2 0 0 1 0 0
Serratia group 0 2 1 1 0 3 0 0 0 1 0 0
Stenotrophomonas 
maltophilia 0 0 1 0 0 1 0 0 0 1 0 0
Streptococcus bovis group 0 0 0 0 0 0 0 0 1 0 0 0
Streptococcus milleri 
group 0 0 0 0 0 0 1 0 0 0 0 0
Streptococcus pyogenes 1 1 0 0 1 0 2 2 1 1 0 0
Streptococcus viridans 
group 6 2 1 4 7 2 1 2 2 4 1 0
Streptococcus, other beta-
haemolytic 2 0 1 1 0 0 1 2 1 2 0 0
Other bacteria 6 3 3 5 10 7 5 7 2 6 3 0
bacteria, total 131 109 126 136 144 123 139 114 79 96 103 67
Candida albicans 1 1 2 1 0 1 0 0 0 0 1 0
Other candida species 1 0 3 1 3 4 1 0 1 0 2 1
Other fungi 0 0 0 0 0 1 0 0 0 0 0 0
fungi, total 2 1 5 2 3 6 1 0 1 0 3 1
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Table 23. Cerebrospinal fluid culture findings in patients aged 65 or over, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Staphylococcus aureus 2 7 7 5 3 2 3 6 5 5 2 10
Staphylococcus 
epidermidis 7 5 6 10 9 12 10 6 2 4 7 7
Streptococcus pneumoniae 4 5 4 8 10 4 7 10 6 7 4 6
Staphylococcus, other 
coagulase-negative 5 4 5 5 3 2 3 3 3 1 3 5
Listeria monocytogenes 2 4 2 4 3 2 2 2 6 4 4 4
Propionibacterium species 4 0 1 0 2 0 2 2 1 1 2 3
Pseudomonas aeruginosa 0 0 1 0 1 0 2 0 0 0 1 2
Citrobacter species 0 0 0 0 0 0 0 0 0 1 0 1
Enterobacter species 2 0 1 0 0 1 0 0 1 1 1 1
Escherichia coli 1 2 2 1 1 0 1 1 1 2 1 1
Neisseria meningitidis 0 1 1 2 1 0 1 0 2 0 1 1
Streptococcus agalactiae 0 1 0 0 0 0 0 1 1 0 0 1
Streptococcus, other beta-
haemolytic 0 2 0 1 0 0 0 1 0 0 0 1
Acinetobacter species 2 1 0 0 1 1 0 0 0 0 0 0
Bacillus 3 0 0 0 0 0 1 0 0 2 1 0
Bacteroides fragilis group 0 0 0 0 0 0 0 1 0 0 0 0
Corynebacterium species 0 1 0 0 0 0 0 0 1 0 0 0
Enterococcus faecalis 2 3 0 2 2 3 0 1 0 0 1 0
Enterococcus faecium 0 1 0 0 0 0 0 1 0 0 1 0
Enterococcus, other or 
unidentified 1 0 0 0 0 0 0 0 1 0 0 0
Haemophilus influenzae 0 0 0 1 2 2 1 1 0 1 0 0
Klebsiella species 0 0 0 0 0 0 1 1 0 0 0 0
Mycobacterium avium 0 0 0 1 0 0 0 0 0 0 0 0
Mycobacterium, other 
than avium 1 4 1 3 0 0 1 1 0 1 0 0
Peptostreptococcus and 
Peptococcus 0 1 0 0 0 0 0 0 0 0 1 0
Proteus mirabilis 0 0 0 0 0 0 1 1 0 0 0 0
Proteus vulgaris 0 0 0 1 0 0 0 0 0 0 0 0
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Pseudomonas, other than 
aeruginosa 0 0 1 0 0 0 0 0 0 0 0 0
Serratia species 0 0 1 0 0 0 0 0 0 0 0 0
Stenotrophomonas 
maltophilia 0 0 1 0 0 0 0 0 0 0 0 0
Streptococcus bovis group 0 0 0 0 0 0 0 1 0 0 0 0
Streptococcus milleri 
group 0 0 0 0 0 0 0 1 0 0 0 0
Streptococcus pyogenes 2 0 0 0 0 0 0 0 0 0 0 0
Streptococcus viridans 
group 1 0 1 0 1 1 0 3 1 0 0 0
Other bacteria 3 2 1 2 3 2 1 1 5 3 0 1
bacteria, total 42 44 36 46 42 32 37 45 36 33 30 44
Candida albicans 0 0 0 1 0 0 1 0 0 0 1 0
Other candida species 2 0 1 0 2 0 0 2 0 2 0 0
fungi, total 2 0 1 1 2 0 1 2 0 2 1 0
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Table 24. Blood culture findings in all age groups, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Escherichia coli 1846 2011 2225 2455 2563 2651 2813 2991 3223 3475 3455 3877
Staphylococcus aureus 996 983 1064 1016 1241 1187 1267 1290 1383 1491 1500 1602
Klebsiella species 377 386 514 542 482 509 631 660 682 646 765 786
Streptococcus pneumoniae 642 766 741 733 744 783 919 852 831 774 748 718
Staphylococcus epidermidis 649 608 683 709 686 665 687 678 697 644 547 626
Streptococcus, other beta-
haemolytic 179 207 240 238 306 289 290 340 393 407 415 478
Staphylococcus, other 
coagulase-negative 321 262 285 273 298 337 362 351 335 345 311 436
Pseudomonas aeruginosa 226 240 204 245 219 262 268 265 318 293 331 325
Bacteroides fragilis group 158 177 189 221 204 218 256 233 289 314 286 305
Enterobacter species 147 169 162 170 186 185 210 216 260 256 274 282
Streptococcus viridans 
group 209 255 277 283 274 265 309 313 336 308 194 268
Streptococcus agalactiae 173 169 186 256 212 213 240 250 290 230 242 256
Streptococcus pyogenes 150 119 140 110 162 208 220 196 171 168 216 191
Streptococcus milleri group 78 91 93 107 132 118 127 121 129 145 144 190
Proteus mirabilis 72 73 97 69 87 109 113 120 132 115 154 141
Citrobacter species 56 55 64 59 71 56 90 90 109 87 121 123
Serratia group 33 44 32 50 49 56 78 65 82 92 90 115
Bacillus 34 39 29 37 46 37 46 38 43 51 40 65
Fusobacterium species 34 28 46 43 31 51 46 36 55 46 68 60
Listeria monocytogenes 20 32 25 30 38 36 34 30 61 38 54 58
Peptostreptococcus and 
Peptococcus 36 43 28 38 40 36 26 56 52 58 43 54
Salmonella, other than 
Typhi 21 28 42 44 63 71 69 33 56 43 51 51
Morganella morganii 16 14 18 24 22 33 25 26 35 38 23 48
Haemophilus influenzae 25 75 25 44 32 54 44 46 40 64 80 44
Clostridium perfringens 33 37 38 46 48 53 44 66 57 59 67 43
Acinetobacter species 42 23 31 31 32 36 28 39 34 40 35 37
Clostridium, other or 
unidentified 53 34 43 46 46 50 39 49 60 44 46 31
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Streptococcus bovis group 10 12 24 21 23 24 16 33 19 18 23 30
Stenotrophomonas 
maltophilia 18 14 25 19 18 18 22 22 23 13 16 27
Capnocytophaga 
canimorsus 7 7 7 9 12 10 11 13 13 23 20 26
Prevotella species 15 15 23 25 21 16 25 28 28 30 23 21
Pseudomonas, other than 
aeruginosa 10 11 8 12 9 16 19 21 17 15 19 21
Bacteroides, other than 
fragilis group 8 5 13 6 7 8 13 23 9 15 19 19
Veillonella species 2 4 2 13 7 11 12 12 10 19 11 19
Propionibacterium species 24 16 14 22 16 10 8 18 16 23 15 17
Neisseria meningitidis 34 30 28 28 32 29 22 24 30 26 21 16
Proteus vulgaris 7 11 11 12 16 12 6 7 10 10 15 16
Campylobacter species 10 11 18 8 8 11 12 17 13 5 10 12
Haemophilus, other than 
influenzae 6 3 8 9 6 4 5 1 3 4 13 11
Hafnia alvei 2 6 8 7 3 7 11 13 9 3 10 7
Salmonella Typhi 2 5 5 6 3 6 1 3 9 5 1 6
Enterococcus, other or 
unidentified 32 31 29 28 27 21 34 35 38 45 43 5
Mycobacterium avium 1 1 0 3 2 2 2 2 2 2 3 5
Mycobacterium, other or 
unidentified 1 6 3 1 7 4 4 0 5 4 2 4
Yersinia pseudotuberculosis 3 3 3 2 1 1 1 3 1 0 2 1
Enterococcus faecalis 263 243 283 302 309 339 311 343 341 387 310 0
Enterococcus faecium 107 130 147 144 183 217 220 273 280 307 200 0
Yersinia enterocolitica 1 3 1 2 1 1 0 2 2 0 3 0
Other bacteria 188 191 211 215 212 191 244 237 239 256 261 320
bacteria, total 7377 7726 8392 8813 9237 9526 10280 10580 11270 11481 11340 11793
Candida albicans 80 109 99 86 113 113 126 105 154 140 128 144
Other candida species 62 83 52 48 46 56 69 70 70 77 72 102
Other fungi 3 6 2 4 4 4 6 5 2 10 2 5
fungi, total 145 198 153 138 163 173 201 180 226 227 202 251
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Table 25. Cerebrospinal fluid culture findings in all age groups, 2002–2013 (no. of cases).
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Streptococcus pneumoniae 28 47 35 28 33 27 38 35 25 24 23 25
Staphylococcus aureus 9 22 28 16 12 21 21 24 20 27 22 23
Staphylococcus 
epidermidis 44 30 37 49 44 32 43 28 16 18 30 22
Staphylococcus, other 
coagulase-negative 24 13 25 22 15 9 21 15 11 7 12 17
Propionibacterium species 10 7 13 6 7 5 6 6 8 6 7 10
Neisseria meningitidis 27 22 20 22 29 23 9 13 12 11 12 8
Listeria monocytogenes 2 6 3 4 5 3 3 4 7 5 5 6
Enterobacter species 3 0 6 5 2 3 9 4 2 3 6 3
Pseudomonas aeruginosa 5 4 3 4 7 3 6 5 3 1 5 3
Escherichia coli 5 3 4 8 8 4 5 6 4 4 4 2
Haemophilus influenzae 2 5 1 2 2 2 4 3 0 4 1 2
Streptococcus agalactiae 6 2 12 7 8 11 5 7 11 2 4 2
Campylobacter species 0 0 0 1 0 0 0 0 0 0 0 1
Citrobacter species 1 1 1 2 0 2 0 0 2 1 1 1
Corynebacterium species 0 2 1 2 1 1 2 1 2 0 1 1
Klebsiella species 0 0 0 0 0 0 5 4 1 2 1 1
Streptococcus, other beta-
haemolytic 3 2 1 2 0 0 1 4 1 2 0 1
Acinetobacter species 6 2 2 4 5 6 2 3 0 2 2 0
Bacillus 8 0 0 3 7 4 4 0 0 2 3 0
Bacteroides fragilis group 0 0 0 0 1 0 0 1 0 0 0 0
Bacteroides, other than 
fragilis species 0 0 0 0 0 1 0 0 0 0 0 0
Capnocytophaga 
canimorsus 0 0 0 0 0 0 0 1 0 0 1 0
Enterococcus faecalis 4 7 7 6 8 9 4 4 5 3 4 0
Enterococcus faecium 2 1 3 1 1 1 0 2 0 2 3 0
Enterococcus, other or 
unidentified 2 0 0 0 1 1 1 0 1 1 0 0
Haemophilus,other than 
influenzae 0 0 0 0 0 1 0 0 0 2 0 0
Morganella morganii 1 0 0 0 0 0 0 0 0 0 0 0
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2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Mycobacterium avium 0 0 0 1 0 0 0 0 0 0 0 0
Mycobacterium, other 
than avium 3 6 1 3 0 1 3 1 1 1 2 0
Peptostreptococcus and 
Peptococcus 0 3 0 0 1 0 0 1 0 0 1 0
Prevotella species 1 0 0 0 0 0 0 0 0 0 0 0
Proteus mirabilis 0 0 0 0 0 0 1 1 0 1 0 0
Proteus vulgaris 0 0 0 1 0 0 0 0 0 0 0 0
Pseudomonas, other than 
aeruginosa 0 1 1 0 1 1 1 1 0 1 0 0
Salmonella, other than 
Typhi 0 1 0 0 0 0 2 0 0 1 0 0
Serratia species 0 2 3 1 0 3 0 0 0 1 0 0
Stenotrophomonas 
maltophilia 0 1 2 0 0 1 0 0 0 1 0 0
Streptococcus bovis group 0 0 0 0 0 0 0 1 1 0 0 0
Streptococcus milleri 
group 0 0 0 0 0 0 1 1 0 0 0 0
Streptococcus pyogenes 4 1 0 0 1 0 2 3 1 1 1 0
Streptococcus viridans 
group 7 4 3 4 10 3 1 7 3 5 1 0
Other bacteria 16 6 5 12 14 9 12 12 8 13 5 4
bacteria, total 223 201 217 216 223 187 212 198 145 154 157 132
Candida albicans 1 1 3 2 0 1 1 1 0 0 3 0
Other candida species 3 0 4 1 5 4 1 2 1 2 2 1
Other fungi 0 0 0 0 0 1 0 0 0 0 0 0
fungi, total 4 1 7 3 5 6 2 3 1 2 5 1
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